01 Oct 2017
Home
File List, RICO
1988 Steere says Lyme is like a B cell leukemia
Assoc Blogs-n-Webs:
TruthCures.org
badlymeattitude.com/
immune2lies.com/
researchfraud.com/
may12.org
meadvocacy.org/
truthbetoldx81
lymecryme
CrymeDiseaseNorway
crymedisease
theothersideofthestretcher
rjspiritualityandtuth
LymeTruthSite
JC-LilnkedIn
KD-Linkedin.com
LD-LinkedIn
JC-academia.edu
KD-academia.edu
CDC "SPIDER"
Fungal Exosomes Inhibit Apoptosis
IDSA:
"Vaccines serve the mfgs, not their victims"
RICO_filed_USDOJ
BlumenthalAntiTrust Lawsuit
Exosomes, Blebs
Spirochetal_Dementia
PDFs
CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler,
1994
BarbourFish, 1993
Dearborn,
1994
BarbourFishpdf.pdf
Pathogenic Fungi
Bush's warcrimes, Oct 2000
Trainer
170708 |
| |
923 |
18 U.S.C. § 371—Conspiracy to Defraud the
United States |
http://www.justice.gov/usao/eousa/foia_reading_room/usam/title9/crm00923.htm
"In summary, those activities which courts have held defraud the United
States under 18 U.S.C. § 371 affect the government in at least one of three
ways:
- "They cheat the government out of money or property;
- "They interfere or obstruct legitimate Government activity; or
- "They make wrongful use of a governmental instrumentality.
In this case, the
ALDF.com, which consisted of
CDC officers as members of this astroturf-, fake non-profit, the ALDF.com
and the EUCALB, conspired to falsify the case definition of "Lyme disease"
to suit their
own commercial
enterprise of vaccines and test kits for emerging vector-borne diseases.
1. ALDF-CDC Enterprise Conspires to Defraud USA in Dearborn-Vaccine Scam
2. Lyme Disease Patents
3. Lyme Disease Biomarkers
4. Patient’s Guide to NIH’s Post Sepsis Syndrome
5.
The Primers
Shell Game (new)
6. New
16 Scientific Articles on NIH's Post-Sepsis Syndrome as
Chronic Lyme /LYMErix disease and "Immunoparalysis"
If you're serious about this BULLSHIT, please join us at the OCCUPY JUSTICE
this Spring (June, mostly); Serious people only please, no complainers and
no talking about your own misery story, Be there for the OTHER GUY (or kid):
“I don’t think it’s appropriate to force people to undergo, to have their
children undergo a medical procedure in this country,” Mr. Kennedy said in a
segment on KOIN-TV in Salem. “I think it’s against the tenets of our
country.”
http://www.washingtontimes.com/news/2015/mar/16/robert-kennedy-jr-presses-states-to-rethink-child-/#ixzz3Uoqhe2Jo
You can tell there is no real sane
leadership in America if we have to tell you what OspA is, while
Anthony Fauci says he does not know what OspA is, ... while he has patent
for an HIV vaccine with OspA (Pam3) stuck on it
6,911,527 ,... and also a patent
for the treatment of OspA disease
5,696,079. Shit you just
can't make up:
"Illustrative of specific disease states in treatment of which the present
invention can be applied are HIV infection and other diseases characterized
by a decrease of T-cell immunity, for example, mycobacterial infections like
tuberculosis and fungal infections such as cryptococcal disease. This method
also can be used in the treatment of secondary infections that occur in
patients with suppressed immune systems, such as the opportunistic
infections that occur in AIDS patients."
Everyone fusses about no NIH funding when the jerks who are employed
by the HHS.gov are all patenteering fools. So now they complain that because
they effed up by putting potential personal patent profits before people,
they find themselves really behind the global medical research game.
Who could have guessed that the effing retarded
HHS.gov said the very thing that caused MS, RA, Lupus, and most cancers, was
a "vaccine?"
Some of the major Criminal Charge Sheets for the USDOJ OCCUPY and
Explainer Handouts are available to download from
http://www.ohioactionlyme.org
and the
Bad Ass Cryme Blog
Latest:
https://badlymeattitude.files.wordpress.com/2015/03/patients-guide-to-nihs-post-sepsis-syndrome-2.pdf
Extended Data on the same:
New Science-Policy
paper on ME/CFS, - and the CDC's Data on the Failed Autism Vaccines - using the IDSociety.org's
and the CDC's own data and Policy-Papers.
News from the Bright Side,
people; We're sharing our star linguist, Bad Ass Cryme
blogger's now hugely popular report on ME/CFS and Post-Sepsis Syndrome - a
disease and disorder and name endorsed and reported on by the NIH:
http://badlymeattitude.com/2015/01/05/m-e-cfsfibromyalgialymeautismgws-post-sepsis-syndrome/
Criminal Charge Sheets for the USDOJ
OCCUPY, May 30th to 4th July, 2015
The CDC's Dearborn and Lyme Vaccine Scam
(150310)
The testing for
Lyme disease was falsified to pass off
bogus vaccines and test kits – a
chronology:
Originally,
Lyme borrelia were perceived by the CDC
to be just another group of Relapsing
Fever organisms. Borreliae (the whole
genus) undergo constant antigenic
variation, making vaccines and valid
testing impossible except for a
flagellin method. At some point, it was
decided by CDC officers that they should
commercialize Lyme and other emerging,
tick-borne diseases by patenting
vaccines and test kits based on
recombinant antigens, anyway. No one
knows who gave the CDC the authority to
do this, but this decision coincided
with the establishment of the fake
non-profit, the American Lyme Disease
Foundation (ALDF.com), Valhalla, NY, in
1990, by Edward McSweegan, Durland Fish,
Gary Wormser, and John J. Connolly, the
then-president of New York Medical
College in association with
Kaiser-Permanente, who are still at NYMC
writing MD-training modules. (CDC is
often found in collaboration with
Kaiser-Permanente; we knew this even
before their “Morgellon’s investigation”
scam.)
The ALDF.com is a False
Claims-and-Racketeering organization,
where the wealthy “sponsors” were
apparently given some inside information
regarding the companies that would be
manufacturing the bogus recombinant
vaccines and test kits. Those companies
would be given some assurance against
the prosecution of the testing scam
necessary to pass off these bogus
recombinant products. The Defendants,
via changing the diagnostic standard,
claimed Lyme was not just another
Relapsing Fever organism, but some
entirely different disease. Yet,
spirochetes were for the last 100+ years
known to be permanent brain infections;
rodent brains used to be the storage
media (Barbour, 1986) before the CDC
learned how to freeze-dry spirochetes
(1964):
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC373079/pdf/microrev00055-0033.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC277387/pdf/jbacter00438-0287.pdf
The ALDF.com Defendants even changed the
disease’s name to “Lyme disease” from
“Lyme borreliosis.” The participants in
the scam even referred to themselves as
an “enterprise” (Arthur Weinstein,
1998).
The Defendants conspired to make Lyme
disease largely undetectable. The plan
was to vaccinate ~5000 people and send
them out in the world to see if they got
Lyme disease. They then would test the
people who became ill, with a test that
only detects 15% of the cases. If Lyme
disease is only 15% detectable, the
Defendants would be guaranteed to have
an at least 85% “effective” vaccine. If
they maliciously discredited the people
who became ill as a result of the
vaccine itself or vaccine failure
(Lyme), then the vaccine would be
“safe,” too. We call both the crime of
falsifying the testing and the resultant
– and current – bogus testing criteria,
“Dearborn.”
The
problem with this scam was that the
vaccine choice, OspA (Pam3Cys or a
tri-acylated lipoprotein), was a fungal
antigen, a TLR2/1-agonist, and as such
caused immunosuppression in humans. It
never could have been a vaccine. Shed
fungal antigens like OspA were the very
things responsible for the New Great
Imitator outcomes. In dogs, Gary Wormser
saw the same immunosuppression result
with an OspA vaccine:
2000, Modulation of lymphocyte
proliferative responses by a canine Lyme
disease vaccine of recombinant outer
surface protein A (OspA).
"OspA interferes with the
response of lymphocytes to proliferative
stimuli including a blocking of cell
cycle phase progression.”
http://www.ncbi.nlm.nih.gov/pubmed/10865170
The short version - and even the
technical version -, is that OspA or a
triacyl lipopeptide or Pam3Cys gums up
the immunity-works.
“Changed!!??” Yes, They Changed
the Diagnostic Standard for Lyme
disease.
The following article by Allen Steere is
the foundation of the CDC’s original,
1990, “Lyme disease” “case definition”
blood test (serology). It was later
falsified at a farce of a serology
conference put on by the CDC in 1994 in
Dearborn, MI.
1986, Allen Steere says:
Appearance of a new immunoglobulin
M response and expansion of the
immunoglobulin G response late in the
illness.
“… Using immunoblots, we identified
proteins of Borrelia burgdorferi bound
by IgM and IgG antibodies during Lyme
disease. In 12 patients with early
disease alone, both the IgM and IgG
responses were restricted primarily to a
41-kD antigen. This limited response
disappeared within several months. In
contrast, among six patients with
prolonged illness, the IgM response to
the 41-kD protein sometimes persisted
for months to years, and late in the
illness during arthritis, a new IgM
response sometimes developed to a 34-kD
component of the organism. The IgG
response in these patients appeared in a
characteristic sequential pattern over
months to years to as many as 11
spirochetal antigens. The appearance of
a new IgM response and the expansion of
the IgG response late in the illness,
and the lack of such responses in
patients with early disease alone,
suggest that B. burgdorferi remains
alive throughout the illness.”
http://www.ncbi.nlm.nih.gov/pubmed/3531237
1990,
CDC published this case definition:
http://www.actionlyme.org/CDC_DOCUMENTS_1990.htm
ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr3913.pdf
“Laboratory criteria for diagnosis
”• Isolation of Borrelia burgdorferi
from clinical specimen, or
“• Demonstration of diagnostic levels of
IgM and IgG antibodies to the spirochete
in serum or CSF, or
”• Significant change in IgM and IgG
antibody response to B. burgdorferi in
paired acute – and convalescent-phase
serum samples.”
That means Lyme disease should be
perceived as a relapsing fever organism,
undergoing antigenic variation. Victims
are only able to produce new, IgM bands
if the organism is still alive and not
killed by antibiotics.
Steere also wrote in that same 1986
report (above; basis of the 1990 CDC
case definition) that all you need is
band 41 to diagnose Lyme; just rule out
syphilis. That is important to remember:
You only need band 41, or the
anti-flagellar antibody and the triad of
symptoms to diagnose Lyme with common
sense rule-outs. The US patent
#5,618,533 of Yale’s is for a specific
recombinant fragment of Borrelia
burgdorferi flagellin. It is an
improvement on the band 41-only antibody
test, and is an actual FDA-validation
according to the FDA’s criteria for the
validation of an analytical method (as
shown in the Primers Shell Game criminal
charge sheet).
Before a diagnosis of Lyme, and of
course in all illnesses, it is
recommended to rule out blood cancers.
The symptoms of Chronic Lymphocytic
Leukemia are identical to chronic Lyme
or MS, not to mention the fact that Lyme
and LYMErix both are known to cause
cancer (and MS, Lupus, possibly RA) via
the reactivation of latent herpes
viruses. Mycoplasma are also known to
be associated with the production of
cancer. Chronic, late, neurologic Lyme
victims are tolerized to these fungal
type-, TLR2/1-agonist bearing diseases.
The truth about the “New Great Imitator”
is that it is these other, secondary,
opportunistic herpes viruses and other
bacterial/fungal infections are
responsible for that variety show of
outcomes. It’s similar to AIDS. It is
Post-Sepsis Syndrome.
This is the current, 1994, CDC
falsified, Dearborn case definition:
http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm
“It was recommended that an IgM
immunoblot be considered positive if two
of the following three bands are
present: 24 kDa (OspC)*, 39 kDa (BmpA),
and 41 kDa (Fla) (1).
“It was further recommended that an IgG
immunoblot be considered positive if
five of the following 10 bands are
present: 18 kDa, 21 kDa (OspC)*, 28 kDa,
30 kDa, 39 kDa (BmpA), 41 kDa (Fla), 45
kDa, 58 kDa (not GroEL), 66 kDa, and 93
kDa (2).”
This 1994, current, criteria is very
different from the 1990 criteria and
basically refers to only the late, HLA-linked,
arthritis, hypersensitivity response. It
came about as a result of research fraud
committed by Allen Steere in Europe in
1992. OspA and B (bands 31 and 34) are
notably absent.
As an aside, we can assume that the
reason the IDSA/ALDF/CDC/Yale Lyme
Defendants do not want anyone treated
for Lyme is because late in the disease,
it’s really about fungal antigen
tolerance and cross tolerance, as well
as reactivated herpes viruses, or is
NIH’s incurable Post-Sepsis Syndrome.
This outcome is paralleled in many other
conditions such as the failed
Tuberculosis vaccines, Malaria and
Epstein-Barr resulting in Burkitt’s
lymphoma, etc. See more at:
http://badlymeattitude.com/2015/01/05/m-e-cfsfibromyalgialymeautismgws-post-sepsis-syndrome/
http://www.actionlyme.org/SASH_POLICYPAPER_MECFS.htm
Most recently (March 2015) the IDSA had
this to say, confirming our supposition:
"Likewise, the use of broad spectrum
gram-negative coverage is not
recommended in most common,
uncomplicated SSTIs and should be
reserved for special populations, such
as those with immune compromise."
http://www.the-hospitalist.org/article/infectious-diseases-society-of-america-2014-practice-guidelines-to-diagnose-manage-skin-soft-tissue-infections/
Treatment of “Lyme” would allegedly
compromise the treatment of severe
sepsis infections by creating an
environment where those secondary
infections acquire antibiotic resistance
genes from Lyme victims being treated
with the tougher antibiotics. The
truth, however, is that most infectious
disease pathogens pick up resistance
genes in swine lagoons. Go ahead and
look that up in the National Library of
Medicine. That should be well known by
normal people (excludes the CDC and IDSA).
How Lyme and OspA cause disease we
learned from the LYMErix fiasco, because
the fungal OspA vaccines caused the same
systemic, protean, post-sepsis syndrome,
chronic active infections/disease (per
Ben Luft and Dave Persing, and the
vaccine victims themselves as reported
to the FDA through the VAERS; see below
for those links and quotes).
Follow: First, Lyme was a plain
old regular Relapsing Fever organism and
the “New Great Imitator!" because it
caused ALS, Lupus, MS, Cancer, RA,
stroke, etc. Later, at the same time
the crooks had a vaccine candidate in
early phase trials, it became nothing
and a non-disease (psychiatric and
hysteria, etc., Barbour and Fish, 1993).
We were then about to get “a vaccine for
a disease that causes no illness.” This
is still the current position of Yale,
CDC, IDSA, and the ALDF/EUCALB: “Lyme
patients are not sick, and OspA was a
vaccine.”
IDSociety.org likes to say what diseases
are-not, but they never say what
diseases are. MD-America does not even
notice that the CDC and IDSA are insane,
even after the FDA ordered LYMErix off
the market in February 2002, after
Senator Richard Blumenthal (a former
USDOJ prosecutor) sued them for
Anti-Trust, after Edward McSweegan
became America’s infamous NIH employee
as America’s one and only “Man With No
Work” (Google that), and even after
Senators Markey, Blumenthal, et al,
ordered the FDA to assure Lyme testing
was valid according to the FDA’s
criteria.
Continuing the Chronology of Events in
Redefining Lyme as a Non-Disease to Pass
Off a Bogus Vaccine:
1986,
Edward McSweegan, in a fake
whistleblower letter to Senator Barry
Goldwater, trashed U.S. Navy to divert
their vector borne diseases funding to
his buddies at the ALDF.com cabal. See
the Navy’s furious response in the link
below. McSweegan thinks there can be a
vaccine for Relapsing Fever, confirming
the paraphysical theory that arrogance
is the seed corn or germinal element in
true, genuine stupidity and/or the
development of a criminal mind:
http://www.actionlyme.org/GOLDWATER_LETTER.htm
1988,
Raymond Dattwyler, JJ Halperin, et al, &
immune-suppressing, seronegative Lyme;
supernatant (lipid layer) of borrelia
mash causes NK cell anergy or a blunted
immune response. Later, Dattwyler tells
the FDA Vaccine committee that the
seronegative patients are the sickest
(now we know why, as shown above where
Lyme and LYMErix are the Great
Detonators of the latent herpes viruses
and expanded or cross tolerance to other
antigens than TLR2/1-agonist bearing
kinds; in short, they’re double-fatigued
and neurologically damaged):
Seronegative Lyme disease.
Dissociation of specific T- and
B-lymphocyte responses to Borrelia
burgdorferi.
"We conclude that the presence of
chronic Lyme disease cannot be excluded
by the absence of antibodies against B.
burgdorferi and that a specific T-cell
blastogenic response to B. burgdorferi
is evidence of infection in seronegative
patients with clinical indications of
chronic Lyme disease."
"The disorder in
these seronegative patients reflected a
dissociation between T-cell and B-cell
immune responses, in which the
cell-mediated arm of the immune response
was intact yet the humoral portion of
the immune response to B. burgdorferi
appeared to be blunted. This diminished
antibody response is in contrast to the
T-cell anergy commonly observed in
several chronic infections (e.g.,
infection with Mycobacterium leprae or
M. marinum, filiarasis, and some chronic
fungal infections (29-33)."
http://www.ncbi.nlm.nih.gov/pubmed/3054554
http://actionlyme.org/DATTWYLER_NK_SUPPRESSION.htm
And:
Modulation of natural killer cell
activity by Borrelia burgdorferi.
"Effect of B burgdorferi Culture
on Normal PBL
...when lymphocytes are
cultured in the presence of growing Bb
there is a marked inhibition ( p < .0005
) of NK activity on days 3, 5, and 7
when compared to lymphocytes cultured in
BSKII media in the absence of
spirochetes. This effect is not due to a
selective depletion or toxicity to
endogenous NK since viability studies
and monoclonal antibodies demonstrate no
significant changes after culture with
the organism.
"The inhibition is directly attributable
to the organism or its supernatants
(data not shown)."
http://www.ncbi.nlm.nih.gov/pubmed/3056196
1990,
CDC: "Diagnose Lyme as if it was
Relapsing Fever" as previously
mentioned.
http://www.actionlyme.org/CDC_DOCUMENTS_1990.htm
1990,
Allen Steere reports that "chronic,
neurologic Lyme won't test positive,"
uses Dattwyler and Volkman’s
Seronegative Lyme T Cell Assay
CHRONIC NEUROLOGIC MANIFESTATIONS
OF LYME DISEASE (NEJM)
"METHODS
”Neurological Evaluation…
”If the patient was seronegative
according to these methods, the serum
was further tested by immunoblotting
(25) and peripheral blood mononuclear
cells were tested for reactivity with
borrelial antigens by proliferative
assay. (26)"
http://www.nejm.org/doi/pdf/10.1056/NEJM199011223232102
http://www.actionlyme.org/STEERES_SERONEG_LYME_ASSAY.htm
http://www.actionlyme.org/DATTWYLER_NK_SUPPRESSION.htm
And what was reference number 26?
>>> Seronegative Lyme disease;
dissociation of the specific T- and B-
lymphocyte responses to Borrelia
burgdorferi
- by Raymond Dattwyler, et al, see 1988
above.
http://www.ncbi.nlm.nih.gov/pubmed/3054554
1990,
ALDF.com founded-- a self-proclaimed
“entrepreneurial quartet.” includes
McSweegan, Fish, Wormser and Connolly.
(You will want to look at who are their
sponsors and on their board, seriously.)
http://www.actionlyme.org/CONNOLLY_FISH_WEINSTEIN.htm
http://www.actionlyme.org/ALDF_BOARD.htm
1992,
CDC officer Allen Steere falsifies
testing in Europe:
http://www.actionlyme.org/STEERE_IN_EUROPE.htm
The PubMed links to those 2 reports – no
full text available, that is why I got
them out of the Yale Medical Library in
2002 and scanned them in are:
Antibody responses to the three
genomic groups of Borrelia burgdorferi
in European Lyme borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/8106763
Western blotting in the serodiagnosis of
Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/8380611
Of those two reports of Steere’s lab
shenanigans in Europe, only the second
one is made a part of CDC’s Dearborn
booklet. The first one – the one left
out of the Dearborn booklet – is where
you can see how he falsified the testing
for his later monopoly on
post-LYMErix-approval for North America,
with Corixa, Yale’s L2 Diagnostics and
Imugen.
These entities are officially listed on
the Securities and Exchange Commission
(SEC) as “partners” in sharing licensing
of the RICO Monopoly patent with the
strain of Borrelia that had dropped an
OspA-B plasmid under US Patent
6,045,804. We will come to this later,
as it is critical to the whole scam and
shows the intent of their entire
enterprise. Steere, in Europe used bogus
“high-passage” borreliae strains that
drop plasmids, and recombinant OspA and
B without the lipids attached, helping
leave OspA and B out of the diagnostic
standard (see the Dearborn criteria
above, there is no OspA or B, bands 31
and 34). The lipid parts of the
lipoprotein are known to be
immune-stimulatory, or to produce
antibodies, so they obviously are
necessary to come up with a legitimate
criteria.
The following is the text (not in the
abstract) of what is in the report on
exactly how Steere defrauded the U.S.
Government and people:
Antibody responses to the three
genomic groups of Borrelia burgdorferi
in European Lyme borreliosis.
“The group 1 strain of B.
burgdorferi, G39/40, used in this study
and in the previous study of US patients
was isolated from an Ixodes dammini tick
in Guilford, Connecticut [21]. The group
2 strain, FRG [Federal Republic of
Germany], was isolated from Ixodes
ricinus near Cologne [22]. The group 3
strain, IP3, was isolated from Ixodes
persulcatus near Leningrad [23]. All
three strains used in this study were
high passage isolates, which were
classified by Richard Marconi (Rocky
Mountain Laboratory, Hamilton, MT) using
16S ribosomal RNA sequence determination
as described [11, 24]. The recombinant
preparations of OspA and OspB used in
this study were purified maltose-binding
protein-Osp fusion proteins derived from
group 1 strain B31 [25]. The fusion
proteins contained the full-length OspA
or OspB sequence without the lipid
moiety or the signal sequence…"
http://www.ncbi.nlm.nih.gov/pubmed/8106763
The following is what it says in the
Persing/Schoen/Steere or Imugen RICO
Monopoly patent, that shows the intended
monopoly - which required that OspA and
B be missing from the diagnostic panel
and from the spirochetes used to test
the human population after the
population was vaccinated with OspA:
Method for detecting B.
burgdorferi infection
"…Additional uncertainty may
arise if the vaccines are not completely
protective; vaccinated patients with
multisystem complaints characteristic of
later presentations of Lyme disease may
be difficult to distinguish from
patients with vaccine failure."
"The present invention provides a method
useful to detect a B. burgdorferi
infection in a subject. The method
provided by the invention is
particularly useful to discriminate B.
burgdorferi infection from OspA
vaccination, although it is sufficiently
sensitive and specific to use in any
general Lyme disease screening or
diagnostic application. Thus, the method
of the invention is particularly
appropriate for large scale screening or
diagnostic applications where only part
of the subject population has been
vaccinated or where the vaccination
status of the population is unknown. "
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
The monopoly on
post-LYMErix-FDA-approval testing for
all vector borne diseases in America and
Canada was their stated intention
(entrepreneurial or enterprise = RICO).
Once LYMErix was on the market, a strain
of borreliae that did not have the
vaccine antigens in it would have to be
used. Vaccine efficacy is never assessed
with the very same antigen as the
vaccine antigen. Otherwise, it would not
be known if the victim has the actual
infection in question, or that the
antibody that shows up came from the
vaccine. This Lyme/Vector-Borne Diseases
monopoly depended on LYMErix being on
the market. That way, Corixa, L2
Diagnostics and Imugen would be the only
labs in the country licensed to use this
RICO strain. They would have access to
all the human blood to pharm all sorts
of DNA data to patent from humans as
well as any new and emerging infectious
diseases. That was the monopoly: LYMErix
and the bogus testing criteria together
with Persing’s RICO patent meant even
more vaccine patents in the future. The
three, Corixa, Imugen and Yale’s L2
Diagnostics, listed themselves as
“partners” in a Securities and Exchange
Commission announcement and advertised
that this test would be available for
the vaccinated population.
The Defendants falsified the “case
definition” to leave out neurologic Lyme
cases, and they left OspA and B out for
a later monopoly on testing and future
patents. And there, you just read that
that intention is clearly stated in a
patent and method developed by Schoen
and Persing in 1995 (US patent
6,045,804), next:
Borrelia burgdorferi enzyme-linked
immunosorbent assay for discrimination
of OspA vaccination from spirochete
infection.
http://www.ncbi.nlm.nih.gov/pubmed/8968914
1992,
CDC staff, Barbara Johnson and Joe
Piesman, own patents with SmithKline
that show 2 kinds of Lyme, HLA-linked
and non-HLA-linked antigens:
COMPOSITIONS USEFUL IN DIAGNOSIS AND
PROPHYLAXIS OF LYME DISEASE
"Summary of the Invention
"In one aspect, the invention provides
isolated B. burgdorferi antigens which
are regulated and differentiated by
growth of the B. burgdorferi in a tick
vector. Novel antigens of the invention
are listed below in Table I.
"Certain of these antigens are
characterized as being B. burgdorferi
B31 strain specific and major
histocompatibility complex (MHC)
nonrestricted. Certain other of these
antigens are characterized as being MHC-restricted."
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1
Why is the CDC talking about
”MHC-restricted” vs. “MHC
non-restricted?”
What we know that to mean is that
classic “autoimmune” diseases tend to be
MHC-(or HLA-) restricted, or the
antigens, due to intermolecular forces,
either bind in the HLA groove too
strongly, the HLA-antigen complex is
released as yet another free, new
antigen, or the antigen does NOT bind
tightly enough and the antigen falls out
of the HLA groove to re-stimulate.
This “autoimmune” only is the new
definition Steere claimed in these 1992
reports and at the CDC’s 1994 Dearborn
conference. He falsely claimed Lyme
disease is only the HLA- or MHC-arthritis-restricted
and threw out the other, meningitis
cases.
Yet, here, in their 1992 patents with
SmithKline, the CDC mentions the other
outcome-- the no- or fewer- antibody
result. Therefore, they recognize the
two kinds of Lyme: the 15% of the
population with the Rheumatoid Arthritis
genegtic background or HLA-restricted or
arthritis cases,… and the 85% with
seronegative, neurologic, long term, New
Great Imitator Lyme.
The 85% of the chronic disease sufferers
most likely suffer from the
opportunistics (NIH’s “Post-Sepsis
Syndrome”) from the imunosuppression
that is caused by shed Borrelial
TLR2/1-agonist antigens. Regardless, the
falsified tests result in more early
Lyme cases going undiagnosed and
therefore progressing to permanent
disability and early death.
1993,
Barbour and Fish slam Neurologic Lyme
victims in:
The Biological and Social
Phenomenon of Lyme Disease
Barbour and Fish admit that
Phase I and Phase II trials of OspA
vaccines are underway. Therefore, as is
shown in the Persing RICO Monopoly
patent (US 6,045,804), they already knew
the OspA vaccines were causing a disease
indistinguishable from vaccine failure,
or CHRONIC LYME:
http://actionlyme.org/BarbourFishpdf.pdf
Here would be a good place to show what
data was received by the USDOJ in New
Haven, CT, on this fraud and RICO scam,
because the difference between
neurologic Lyme and arthritis Lyme is so
clear:
Compare the blots from the two kinds of
Lyme in this (above) July 2003 RICO
complaint. On the left with the faint
antibody bands is neurological Lyme (the
sickest, according to Ray Dattwyler),
and on the right are the HLA-linked
outcomes of arthritis and
acrodermatitis:
http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm
Hence, the Defendants left out the
neurological outcomes in their Dearborn
scam. The whole point of the
redefinition of Lyme at Dearborn was to
narrow it to just the HLA-linked,
arthritis, supposedly autoimmune,
hypersensitivity cases. This is how and
why they get away with perjury. When the
IDSA/Yale Lyme Defendants say “Lyme
Disease,” they mean exclusively
“HLA-linked arthritis AND NO OTHER
SYMPTOMS.” No lawyer was or is aware of
this semantics scam.
Jump to 2005; Here Klempner and
Wormser re-revealed that “Lyme disease”
is just one thing: a bad knee and
no other illness signs. However, as
shown above, there are two distinct
outcomes of Lyme borreliosis. The
controversial one (neurologic-, chronic
fatigue- Lyme) really does not have a
name right now. Therefore, “Lyme
disease” is defined as ONLY a bad knee.
It’s a legal definition. It’s also
criminal one, based on fraud and no
consensus, but here is what it is again
(2005):
A Case-Control Study to Examine
HLA Haplotype Associations in Patients
with Posttreatment Chronic Lyme Disease
”… There appear to be at least 2
distinct syndromes after antibiotic
treatment. [They have no data on
un-treated people, obviously, since they
could not ethically conduct such a
study-KMD] One syndrome has localized
symptoms that are similar to
pretreatment symptoms. Patients with
this syndrome often have recurrent
episodes of arthritis/synovitis. Results
of synovial fluid cultures and
polymerase chain reaction (PCR) for B.
burgdorferi are generally negative….
[See the DNA/RNA Shell Game report, this
is not true
http://www.actionlyme.org/PRIMERSHELLGAME.htm
; it’s a shell game; they use DNA that
they know won’t be there in that
sequence due to antigenic variation to
claim “No Lyme here.”-- KMD]
“…Patients generally feel well aside
from their arthritis symptoms.”
http://jid.oxfordjournals.org/content/192/6/1010.full
Let’s restate what Wormser and Klempner
are trying to say in that 2005 report:
-- The people with the falsified
Dearborn case definition of “only an HLA-linked
arthritis in a knee” have only an HLA-linked
arthritis in a knee and no other
symptoms.
-- If you falsify the case definition
and say “ONLY the HLA-linked
hypersensitivity response of bad knee
can be a ‘case’ of ‘Lyme disease,’" you
can then, 11 years later say, “Oh, how
amazing for us to find only the HLA-linked
case definition of arthritis-only is an
HLA-linked arthritis-only, and is only a
bad knee.“
These people are crazy, yes, if that is
what you were thinking.
Also, the CDC recently reacted to the
Senators' (Blumenthal, Markey, et al)
letter to the Office of Policy and
Management, where the Senators are
forcing the FDA to do their jobs and
assure that the testing for Lyme is
validated according to their own FDA
rules. (See the Primers Shell Game for
more on that;
http://www.actionlyme.org/PRIMERSHELLGAME.htm.)
The CDC is trying to say that the
Dearborn method was FDA validated, when
it was not:
”Washington – Senator Edward J. Markey
(D-Mass.) was joined by Senators Richard
Blumenthal (D-Conn.), Elizabeth Warren
(D-Mass.), Sherrod Brown (D-Ohio), and
Dick Durbin (D-Ill.) in calling on the
Obama administration to release draft
guidance to ensure appropriate oversight
of laboratory developed diagnostic tests
(LDTs), which are used to help diagnose
specific forms of cancer and other
diseases and are not approved by the
Food and Drug Administration (FDA).
Laboratories initially manufactured LDTs
that could be used for low-risk
diagnostics or for rare diseases, but
with new technology, they have become a
staple of clinical decision-making and
are being used to diagnose high-risk but
relatively common diseases such as
ovarian cancer. Recently, the Centers
for Disease Control and Prevention (CDC)
reviewed a frequently utilized LDT to
detect Lyme disease and found “serious
concerns” about false-positive results
and misdiagnosis. The CDC recommended
that the diagnosis of Lyme disease
should instead be left to tests approved
by the FDA. ...”
http://politicalnews.me/?id=29174&keys=DIAGNOSES-CONDITIONS-MEDICAL-OBAMACARE
Here are the FDA’s rules for the
validation of an analytical method:
which were met by Yale’s 1991 Flagellin
Method Patent US # 5,618,533 and this
report:
Molecular characterization of the
humoral response to the 41-kilodalton
flagellar antigen of Borrelia
burgdorferi, the Lyme disease agent.
”The
earliest humoral response in patients
infected with Borrelia burgdorferi, the
agent of Lyme disease, is directed
against the spirochete's 41-kDa
flagellar antigen. In order to map the
epitopes recognized on this antigen, 11
overlapping fragments spanning the
flagellin gene were cloned by polymerase
chain reaction and inserted into an
Escherichia coli expression vector which
directed their expression as fusion
proteins containing glutathione S-transferase
at the N terminus and a flagellin
fragment at the C terminus.
Affinity-purified fusion proteins were
assayed for reactivity on Western blots
(immunoblots) with sera from patients
with late-stage Lyme disease. The same
immunodominant domain was bound by sera
from 17 of 18 patients. This domain
(comprising amino acids 197 to 241) does
not share significant homology with
other bacterial flagellins and therefore
may be useful in serological testing for
Lyme disease.”
http://www.ncbi.nlm.nih.gov/pubmed/1894359
As you can see, the FDA has not changed
their rules on how to validate a method:
”Under the FD&C Act, the FDA assures
both the analytical validity (e.g.,
analytical specificity and sensitivity,
accuracy and precision) and clinical
validity through its premarket clearance
and approval process.”
http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407409.pdf
Also, Borrelia burgdorferi is closest
genetically to B. anserina, an African
bird borreliosis, so it is not
surprising that Lyme is found all across
the United States, being carried by
birds:
Many California bird species host the
Lyme disease bacterium, study finds:
http://www.latimes.com/science/sciencenow/la-sci-sn-california-birds-lyme-disease-20150225-story.html
See more at:
http://www.actionlyme.org/PRIMERSHELLGAME.htm
for the phylogeny or the genetics that
shows Lyme is closest to B. anserina
(from Africa).
Therefore there cannot be any “disease
calculator” for Lyme as there
fraudulently had been in the past, in an
attempt to limit diagnoses. Just as all
kinds of Borreliae are everywhere, so is
this specific one, burgdorferi.
Returning to the Chronology of the Crime
1994,
June; FDA LYMErix Meeting (note that
June precedes October--when the Dearborn
stunt took place-- so the FDA never
approved of the Dearborn method, not to
mention it was research fraud, and not a
consensus):http://www.actionlyme.org/1994_FDA_MEETING_LYMERIX.htm
Transcript of June 1994 FDA Meeting
Minutes on Lyme and potential vaccines:
Dr.O’BRIEN: “I was concerned about your
last slide where you said there was a
poor correlation between serologic
response and clinical disease. And as I
heard you to say, some people who mount
better immune responses get worse
disease. Did I hear you say that?”
DR. DATTWYLER: “No, no, I said the
reverse. The better responses tended to
have better response. And I should
clarify where this is from. This is from
antibiotic trials. These are treatment
trials of erythema migrans, in which
individuals given an antibiotic regimen
which was not optimal – we did not know
that it was not optimal at the time –
the ones that failed to mount a vigorous
response tended to do worse, clinically.
So, there was an inverse correlation
between the degree of serologic response
and the outcome.
“So, individuals with a poor immune
response tend to have worse disease."
We know why, now, that “individuals with
a poor antibody response have worse
disease.” Borrelial fungal antigens
cause immunosuppression and a classic
post-sepsis-like result with chronic
active EBV, HHV-6, et al. And we know
this is not just from antibiotic
treatment as Dattwyler said at this FDA
meeting--that the diminished responses
are due to the organism or its
supernatants, like OspA, and that that
is typical for fungal infections:
Seronegative Lyme disease.
Dissociation of specific T- and
B-lymphocyte responses to Borrelia
burgdorferi.
”We conclude that the presence
of chronic Lyme disease cannot be
excluded by the absence of antibodies
against B. burgdorferi and that a
specific T-cell blastogenic response to
B. burgdorferi is evidence of infection
in seronegative patients with clinical
indications of chronic Lyme disease.”
”The disorder in these seronegative
patients reflected a dissociation
between T-cell and B-cell immune
responses, in which the cell-mediated
arm of the immune response was intact
yet the humoral portion of the immune
response to B. burgdorferi appeared to
be blunted. This diminished antibody
response is in contrast to the T-cell
anergy commonly observed in several
chronic infections (e.g., infection with
Mycobacterium leprae or M. marinum,
filiarasis, and some chronic fungal
infections (29-33).”
http://www.ncbi.nlm.nih.gov/pubmed/3054554
http://actionlyme.org/DATTWYLER_NK_SUPPRESSION.htm
And:
Modulation of natural killer cell
activity by Borrelia burgdorferi.
"Effect of B burgdorferi Culture
on Normal PBL
"...when lymphocytes are cultured in the
presence of growing Bb there is a marked
inhibition ( p < .0005 ) of NK activity
on days 3, 5, and 7 when compared to
lymphocytes cultured in BSKII media in
the absence of spirochetes. This effect
is not due to a selective depletion or
toxicity to endogenous NK since
viability studies and monoclonal
antibodies demonstrate no significant
changes after culture with the organism.
"The inhibition is directly attributable
to the organism or its supernatants
(data not shown)."
http://www.ncbi.nlm.nih.gov/pubmed/3056196
The diminution of antibody response is
due to the fungal antigens shed by
Borrelia and not antibiotics since this
phenomenon is seen in parallel in other
human fungal-exposure immunology. See
those other scientific examples,
including from the CDC on the failed
Autism vaccines and the failed
Tuberculosis vaccines, here:
http://www.actionlyme.org/SASH_POLICYPAPER_MECFS.htm
1994,
CDC's invitation to participate in the
Dearborn event. Labs were invited; they
said the Steere proposal was only, on
average, 15% accurate; CDC then blew off
these labs’ recommendations:
http://www.actionlyme.org/DEARBORNINVITATION.pdf
1994,
October; CDC's Dearborn Booklet .pdf
http://www.actionlyme.org/DEARBORN_PDF.pdf
Dearborn, Who Said What (also
summarized for the FDA at their Jan 2001
hearing on adverse events to LYMErix):
http://www.actionlyme.org/DEARBORN_WHO_SAID_WHAT.htm
1) Gary Wormser at New York Medical
College reports that Steere’s Dearborn
proposal method detected 9/59 of IgG
cases or is 15% accurate, missing 85% of
the cases:
Serodiagnosis in Early Lyme
Disease
”Overall, 51 of 59 (86%)
convalescent phase serum specimens were
reactive by IB [Dearborn criteria
Immunoblot-KMD], 35 of which were
interpreted as positive; 26 based on IgM
criteria, 8 based on both IgM and IgG,
and 1 based on IgG criteria…”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC266355/pdf/jcm00024-0026.pdf
That is,
according to Gary Wormser, 9 out of 59
cases were positive to Dearborn later in
the disease; Gary Wormser assessing
Steere’s Dearborn panel proposal in this
report, says it only detects 15% of the
cases in IgG.
2) Igenex —Steere’s IgG panel detected
8% of the cases
3) Imugen —Steere’s IgG panel detected
14% of the cases
4) Wisconsin —Steere’s method was 15%
accurate
5) UCONN —Larry Zemel was referring to
Lyme as comparable to only juvenile
rheumatoid arthritis when of course it
isn’t. Recommended adding band 50 for
children’s blots.
6) Roche— 28% were positive for 5 of 10
Steere IgG bands.
7) Wadsworth— had some different scoring
system. Did not report on accuracy of
Steere's method
8) Ontario Ministry of Health—did not
give an assessment of the Steere
proposal (page 86)
9) Lutheran Hospital— 22% were accurate
by Steere’s IgG
10) MarDx Labs— recommended adding bands
31 and 34, but were given CDC positive
arthritis positive blood to falsely
qualify their test strips. Their Western
Blot test strips were used in both OspA
vaccine trials. MarDx was later sold to
an Irish company, Trinity Biotech,
Dublin; all the data they had about this
crime was taken out of the country.
11) CDC Atlanta— talked about mice, not
humans. The mouse criteria was 2 out of
three from OspC, 16 kD, 17.9 kD, for the
mice.
We got this standard anyway, even though
none of the invited participants agreed
- not by a long shot. See the Primers
Shell Game reports here or at this link:
http://www.actionlyme.org/PRIMERSHELLGAME.htm
for an explanation of how VALID testing
is performed according to the FDA rules,
and how Yale knows all about how to
validate a method for Lyme (Bb-specific
flagellar antigen) and patented it (US
5,618,533). This is all obvious criminal
fraud. Yale owned a valid test for Lyme
but did not use it to qualify their
other patented product, rOspA, LYMErix.
Who was
involved with approving the bogus
Dearborn method at Dearborn when all the
invited labs said it was only 15%
accurate (and FDA criterion for
validation)?
None other than the CDC vaccine patent
owners and all the scammers you see
here:
http://www.actionlyme.org/Dearborn_Who_Approved.htm
“Alan Barbour,” “Edward McSweegan,”
“Allen Steere,” “Arthur Weinstein,” "The
CDC Lyme Disease Group" (Barbara
Johnson), etc. (The same people involved
in the OspA vaccines scam were involved
in falsifying the testing and who were
the original members and “advisors” of
the ALDF.com.)
A view of the Dearborn event by a
participant. It’s an independent
paper about it; Igenex’s Nick Harris’
report published in the Lyme Disease
Foundation’s journal:
http://www.actionlyme.org/HARRIS_IGENEX_DEARBORN.pdf
Evidence Lyme Defendants
knew LYMErix produced the same
"multisystem disease" as "Chronic Lyme"
1) Ben Luft said it at the 1998 FDA
meeting:
http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf
BEN LUFT: "The point that I wanted to
make in regard to the study is that
there is very heavy dependence on
serologic confirmation. And when we
start thinking about the adverse events,
*** it was stated originally when we got
the overview of the disease that the
disease is really quite protean. And
actually the adverse events are very
similar to what the disease
manifestations are.**** And if you start
to, as I think Dr. Hall was eluding to
-- if you start to kind of say well how
often do you actually become
seropositive, you can start to have a
different take on when someone has an
adverse event or whether it is disease
specific or infection specific versus
vaccine specific. And I think that that
is an important issue that we have to
deal with. ..."
2) Dave Persing said it in his RICO
patent (above),
Method for detecting B.
burgdorferi infection
"…Additional uncertainty may
arise if the vaccines are not completely
protective; vaccinated patients with
multisystem complaints characteristic of
later presentations of Lyme disease may
be difficult to distinguish from
patients with vaccine failure."
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
3) Fish and Barbour trashed Lyme disease
victims with their “Social Aspects”
report in 1993 (above), paving the way
to slander and libel their future
LYMErix victims. They reveal that the
OspA vaccine trials are underway in that
report. This shows intent to cause harm.
The Biological and Social
Phenomenon of Lyme Disease
http://actionlyme.org/BarbourFishpdf.pdf
4) Dave Persing (who worked on this with
Robert Schoen, as shown above) and his
company Corixa wanted to sell vaccine
adjuvants, but they had to drop OspA as
a candidate adjuvant because, as Persing
said in another patent (applied for May,
2001, while LYMErix was still on the
market, harming people; he never said
anything to the FDA about it):
Prophylactic and therapeutic
treatment of infectious and other
diseases with mono- and
disaccharide-based compounds
"Accordingly, the methods of the
invention provide a powerful and
selective approach for modulating the
innate immune response pathways in
animals without giving rise to the
toxicities often associated with the
native bacterial components that
normally stimulate those pathways."
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/PTO/srchnum.htm&r=1&f=G&l=50&s1=6,800,613.PN.&OS=PN/6,800,613&RS=PN/6,800,613
In this complaint to the UN Human Rights
Commission and the foreign embassies:
http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm
it shows that Corixa got an 11 million
dollar “biodefense contract” from the
NIH and the adjuvants they are allegedly
producing are TLR4 agonists, not TLR2/1
agonists like LYMErix, because Persing
et al know OspA as an adjuvant is
“too toxic in the native form” and
"…Additional uncertainty may arise if
the vaccines are not completely
protective; vaccinated patients with
multisystem complaints characteristic of
later presentations of Lyme disease may
be difficult to distinguish from
patients with vaccine failure,"
which means they know OspA is too toxic
and causes a chronic illness identical
to chronic Lyme.
5) In 1998 Yale’s Robert Schoen wrote
the following article in the ALDF’s
book, Lyme Disease, ACP Key Diseases
Series, published in 1998 to
coincide with the release of LYMErix
onto the market. Once again. Schoen is
paving the way, instructing other
“doctors” to view LYMErix-injured people
and Chronic Lyme victims (which are
essentially the same disease,
Post-Sepsis Syndrome) through the same
victim-blaming lens.
The article is called Clinical
Vignettes, Case 13, A Vaccine Recipient
who Develops Arthralgia and Fatigue,
page 238-9, and is about what to do with
a person who has had the Yale dangerous
rOspA non-vaccine. He says not to test
these LYMErix victims and he minimizes
their symptoms, knowing that late,
neurologic chronic Lyme symptoms are
identical to what Schoen says are
"nonspecific" (fatigue, meningitis,
etc).
Schoen says the exact reverse in the
Persing-Schoen-Corixa-RICO patent (US.
Pat. No. 6,045,804 and associated
journal report,
http://www.ncbi.nlm.nih.gov/pubmed/8968914):
"multisystem complaints characteristic
of late Lyme."
WRITES SCHOEN (you can tell this is BS
because it does not make any real
sense):
”QUESTION
”Is this patient’s presentation
compatible with Lyme disease?
”COMMENT
This patient presents with nonspecific
symptoms, including arthralgias and
fatigue. Although he lives in an area
endemic for Lyme disease, these findings
by themselves do not point to Lyme
disease.
“The risks of a
false-positive serologic test result in
this patient will be significant because
the prevalence of Lyme disease in such
individuals is low. More importantly,
this patient has already received a Lyme
disease vaccine. Because of this, he
will have antibodies against the 31-kd
OspA Borrelia burgdorferi protein.
These antibodies will be directed by the
Lyme ELISA and will generate a positive
test resut.
“In the absence of specific
clinical features suggesting a diagnosis
of Lyme disease, the best course of
action may be not to do serologic
testing for Lyme disease at all. If such
testing is to be done in a person who
has received the Lyme disease vaccine,
it will need to be sent to a laboratory
where the Western blot analysis can be
done that omits the 31-kd response.”
"CONCLUSION:
"In
Lyme disease recipients (sic), Western
blot analysis is indicated to
distinguish Lyme disease from
seroconversion caused by vaccination."
Schoen (above) probably means “In Lyme
disease vaccine recipients,
Western blot analysis is indicated to
distinguish disease from seroconversion
by vaccination.”
This does not make a whole lot of sense
because Schoen first said not to test
them, just blow these people off,
essentially, because their symptoms were
vague (means, “not a red, swollen
knee”). But then Schoen went on to say
that if you MUST test them, use the
Persing-Schoen RICO patent method with
the OspA-B plasmid missing, making it
very clear that the reason OspA and B
were left out of the Dearborn standard
was to satisfy this subsequent
racketeering condition or monopoly on
testing, once LYMErix was on the
market. That is why I call this the
RICO patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
This transcript of Schoen’s “Clinical
Vignettes” above is in that textbook
with the libel and false statements
including the
Munchausen’s accusations:
http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584/ref=sr_1_fkmr0_2?ie=UTF8&qid=1341914626&sr=8-2-fkmr0&keywords=lyme+disease+rhan+and+evans
See more at
http://www.actionlyme.org/SCHOEN_INSTRUCTING_DOCS_TO_BLOW_OFF_LYMERIX_INJUREES.htm
From start to finish, from when the
ALDF.com was established in 1990,… to
Steere going to Europe in 1992 to
falsify the case definition antibody
panel and adding the ridiculous ELISA
“screening test” (for arthritis only)
for a fungal-like disease, … to the CDC
falsifying the testing for Lyme at
Dearborn in 1994, … to lying to the FDA
and the journals about their outcomes of
the 2 vaccine trials in 1998, to fake
“Guidelines” based on the bogus Klempner
non-retreatment non-study in 2001,…. the
point of this scam was to create a
condition where only they
– the CDC staff and the ALDF.com - would
be able to capitalize on vector-borne
diseases vaccines and test kits.
They intended to get all the grants, all
the royalties, and to define the
diseases based on their fake products.
Most importantly, they wanted this
post-:LYMErix monopoly on human blood
testing because they could pharm from
that not only human DNA and disease
susceptibilities, but new vector borne
disease DNA to patent. It was all about
the money. It was all about cornering
the market on this new genre of
potential diseases resulting from global
pollution.
========
Falsifying the Vaccine Trial Results,
Part 2 of the Cryme – the Unreadable
Western Blots.
The 1998 Vaccines Reports (ImuLyme and
LYMErix):
LYMErix results (76% "safe and
effective"):
http://content.nejm.org/cgi/content/abstract/339/4/209
ImmuLyme results (92% "safe and
effective"):
http://content.nejm.org/cgi/content/abstract/339/4/216
From the LYMErix trial, "categories of
outcomes:"
http://content.nejm.org/cgi/content-nw/full/339/4/209/T1
YET, here are the Defendants claiming
"we can't read our OspA vaccine results"
reports, which means they lied in their
OspA vaccine safety and efficacy
reports, since they both claimed to be
using the Dearborn method and MarDx's
Western Blot test strips:
1) Yale’s Robert Schoen and Mayo’s/Corixa’s
David Persing, with John
Anderson,1995-6; the RICO report:
http://jcm.asm.org/cgi/reprint/35/1/233?view=long&pmid=8968914
2) Shoen and Persing in their 1995-6
RICO method patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
3) David Persing and Lenny Sigal
explaining that the Western Blots of
OspA-vaccine victims were not readable
(which means whoever was in charge of
data safety monitoring like Arthur
Weinstein is in big trouble):
http://www.journals.uchicago.edu/doi/pdf/10.1086/313920
4) Yale's Robert Schoen in the 1998
Munchausen's Book, instructing MDs to
blow off LYMErix-systemically-injured
people ("but send the post-vaccination
blood to the Yale L2 Diagnostics RICO
lab if you must bother to be a
physician").
They used the bogus Dearborn method, and
did not report that their Western Blots
were unreadable. Each vaccine trial
report and summary was 2 false claims.
====
In the fall of 1998, the LYMErix
vaccine was approved, anyway, by the FDA
(the FDA panel being loaded with people
like Allen Steere, Robert Schoen, and
Vijay Sikand – the very people who ran
the OspA trials). It came onto the
market in late 1998 “despite numerous
provisos.”
More than 1,000 systemic adverse events
were reported through the VAERS from
September 1999 to November 2000,
whereupon the FDA granted a public
hearing, January 31, 2001:
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2.htm
Whereupon, the whistle was blown on
Dearborn and how LYMErix actually caused
immunosuppression (the FDA did not scan
in the last 19 pages of this booklet,
which were 19 pages out of the Dearborn
booklet, proving no one agreed with
Steere's proposal for an antibody panel
for a "case definition"):
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf
Several months later, in the fall of
2001, Karen Forschner of the Hartford,
CT based Lyme Disease Foundation (Lyme.org)
delivered to the FDA – in person, a
patent owned by Brigitte Huber at Tufts
University, where it was declared that
OspA was technically a “toxin,” right in
the abstract (US Patent 6,689,384). The
FDA then gave SmithKline and Yale, the
assignee of the LYMErix patent, an
ultimatum: “Either you remove LYMErix
voluntarily or we will order it off the
market.” SmithKline chose to avoid the
embarrassment and pulled their own
non-vaccine.
We’re still stuck with this bogus
Dearborn case definition, despite
numerous attempts at lawsuits against
IDSA, SmithKline, and filing complaints
to the U. S. Department of Justice. It
is still very dangerous for the public
to be unaware that the average person,
or 85% of us – who are the "seronegative
patients are the sickest," have no
chance of testing positive to this
criminal CDC-Dearborn standard, because
the actual disease is one of
immunosuppression, or is an Acquired
Immune Deficiency, or is similar to AIDS
with all the opportunistic viral
infections and lymphocyte mutations that
can’t be treated with antibiotics,
alone.
It was said at the time LYMErix was
still on the market that this vaccine,
via its claimed mechanism of
disinfecting ticks with human antibodies
(yes, if you can believe it), that
LYMErix would turn humans into walking
canisters of tick disinfectant, when in
fact, LYMErix turned people into walking
“cesspools of disease.” The same is true
for Chronic Lyme. Chronic Lyme victims’
immune systems are “overwhelmed”- a term
used by CDC officer Alan Barbour, when
describing what antigenic variation in
spirochetes does to humans (US Patent
6,719,983). This is a term you want to
remember in case you hear it again:
“overwhelmed” immune system means:
“turned off.” “Turned off” is the
complete opposite of an “inflammatory”
or “autoimmune disease.”
Charge
One: Falsifying the case definition- a
CDC Staff Conspiracy; Steere, Barbour,
and Johnson
A) CDC officers Allen Steere, Alan
Barbour, Barbara Johnson conspired to
falsify the case definition for Lyme
disease. [Conspiracy to Defraud, see
the ALDF.com as “Astroturf” or a fake
non-profit.]
B) Barbour and Johnson own patents from
which they stood to profit only if the
testing case definition was falsified.
[Theft of Honest Services.]
C) Steere falsified the Western Blot
case definition panel of antibodies
testing in Europe in 1992 via research
fraud, leaving OspA and B out of the
diagnostic standard using recombinant
antigens and high-passage strains that
drop plasmids. This would give the
appearance that OspA and B (encoded on
the same plasmid so they would have to
be dropped together) were not “primary,
immunodominant antigens” which was
contrary to Steere, et al’s previous
claims and the very nature of their
alphanumeric nomenclature (“OspA, OspB,
OspC, OspD, OspE, OspF, etc”
-antigens).
Steere, allegedly, stood to profit with
the secondary outcome of falsified
testing – testing with a method that was
designed by Steere (in Europe) that
would be necessary after an OspA vaccine
was on the market. It left OspA and B
out. OspA and B are encoded on the same
plasmid. Steere’s friends’ companies
were to be the only ones licensed to use
this method
Steere was involved in a monopoly with
RICO entities David Persing (Mayo Clinic
and Corixa), Robert Schoen (Yale’s L2
Diagnostics), and Phillip Molloy
(Imugen) to capture all the post-LYMErix
testing for North America. They publicly
claimed in an SEC filing and in public
announcements/advertisements that they
would be the only labs licensed to test
for Lyme “when the vaccination status of
the population was unknown” (US patent
6, 045,804), or if it was unknown if a
person had had an OspA vaccine or
not. [False Claims, Racketeering]
Charge Two: Steere added an
unnecessary ELISA
screening test that only detects late
Lyme arthritis in the first step and
declared this to be a test for “early
Lyme.”
Steere not only added an ELISA as a
screening test that of (falsely raising
the bar on a total-antibody test) that
left out all neurologic outcomes of Lyme
as “cases,” but the normal cut-off for a
chromatography assay such as this is 3
standard deviations above baseline noise
(that means the signal generated by a
blank). Steere used 5 standard
deviations for a cut-off - another act
of fraud.
It was never necessary to use a
total-antibody test such as an ELISA
since Steere himself knew many patients
produced low antibody concentrations,
having used the Dattwyler-Halperin
Seronegative T cell Proliferation Assay
to assess “Chronic Neurologic Lyme”
victims in 1990.
Charge Three: CDC officer Barbara
Johnson hosted a fake consensus
conference in Dearborn, MI,
in October, 1994, subsequent to Steere
falsifying the testing in Europe with
Frank Dressler (a student in Germany).
Johnson sent out invitations to labs
across the country that were under the
impression the conference would be about
standardization of the METHOD of Western
Blotting (e.g., what concentration of
reagents and strains to use) rather than
the interpretation of the Western
Blots. Only MarDx agreed with the
antibody panel proposed by A from his
European research fraud criteria, but
they, MarDx, had been given
Lyme-arthritis-positive blood (HLA-linked
hypersensitivity response) to qualify
their Western Blot test strips. The
average assessment of the ACCURACY
(cases that were known to be positive
with, for example a DNA method),
excluding MarDx, that were shown to be
positive with this falsified antibody
panel for a “case” of Lyme was 15%.
Johnson ignored all those
recommendations, despite inviting them
to “participate in the proceedings.”
Charge
Four: Falsifying the OspA vaccines
outcomes:
This gang then reported 76% and 92%
“safe and effective” OspA vaccines
(ImuLyme and LYMErix) when the Western
Blots, they later reported, were
unreadable. So, they used a bogus test,
the Dearborn Method (they claimed), to
assess the outcomes of their vaccines,
but they later reported they actually
had no idea if OspA vaccines prevented
Lyme because they could not read their
results.
Charge
Five: Issuing “Guidelines” to have it
appear they believed Dearborn and the
vaccines scam were not fraud
Klempner, the Valid Biomarkers of
Illness vs. IDSA’s “Guidelines.”
http://www.ohioactionlyme.org/wp-content/uploads/2015/02/Biomarkers1.pdf
The IDSA “guidelines” on the “diagnosis
and treatment of Lyme disease” are based
on a 1997-2001 “study” by Mark Klempner,
and are meant to reinforce the false
notion that IDSA thinks Dearborn is
valid, as a sort of a “A Good Offense is
the Best Defense” maneuver.
A) Klempner used the Dearborn case
definition as a case definition.
B) He conducted this so called study in
the first place after publishing that
Lyme was incurable with ceftriaxone even
when the spirochetes had no host cells
to hide within (1992).
C) Klempner allegedly “re-treated”
patients IV ceftriaxone for 30 days,
when 2/3rds of his victims had never had
the standard of care 30 days of IV
ceftriaxone for this known meningitis in
the first place.
D) Klempner is the author of at least
one valid biomarker of central nervous
system degradation (MMP-130, 1992), yet
he used invalid checklists used for
psychiatric patients to assess his
non-re-treatment outcomes.
Note – Senator Richard Blumenthal
admonished IDSA in his lawsuit for a
similar instance where JJ Halperin tried
to pull an “end-run” around the
Blumenthal subpoena, issuing as second
set of false guidelines:
http://www.ct.gov/ag/cwp/view.asp?a=2795&q=414284
”The
IDSA portrayed another medical
association's Lyme disease guidelines as
corroborating its own when it knew that
the two panels shared several authors,
including the chairmen of both groups,
and were working on guidelines at the
same time. In allowing its panelists to
serve on both groups at the same time,
IDSA violated its own conflicts of
interest policy.”
Charge Six: Intent to Cause Harm with
slander, libel and perjury.
This gang trashed the reputations of
their Lyme and LYMErix victims inferring
they were crazy; the UN complaint is
referenced:
http://www.actionlyme.org/UN_PETITION.htm
Charge Seven: The Patents show
contradictory claims
to public claims made by the cabal; each
claim should be examined and be compared
to each Defendant’s public claims about
“Lyme Disease.”
http://www.ohioactionlyme.org/wp-content/uploads/2015/02/Lyme-Disease-Patents8.pdf
The patents make contradictory claims to
what is said publicly about Lyme
disease. What’s in them are point by
point fraud indictments; Lyme is very
serious and incurable; OspA and B were
left out of the standard to serve a
monopoly on testing after an OspA
vaccine was on the market; Barbour owns
Edwin Master’s Southern Lyme Disease
borrelia; LYMErix or OspA was never a
vaccine (Persing).
Charge
Eight: The DNA/RNA Shell Game
– when looking for spirochetes in
humans, they use the wrong DNA. When
looking for organisms to patent by
patenting their specific flagellin gene,
they know how to find Borreliae.
http://www.actionlyme.org/PRIMERSHELLGAME.htm
Charge
Nine: Congenital Lyme;
Yale staff wrote at least 3 reports on
congenital Lyme in autopsy findings and
regarding the effect of maternal
antibodies on the fetus. Later, Yale’s
Eugene Shapiro said publicly that there
never was a known case of congenital
Lyme in the Under Our Skin movie:
http://www.actionlyme.org/Congenital_Brain_Infection_of_Newborn_Resulting_in_Death.htm
Charge
Ten: Pediatric Assault with a fake
vaccine- UConn and Yale.
Testing a known fake vaccine on Czech
children, knowing there was none of that
kind of OspA in Europe just to see how
serious would be the adverse events.
This is technically known as “assault.”
http://www.actionlyme.org/UCONNS_ABUSE_OF_CZECH_CHILDREN.htm
The “Lyme Disease” Patents
– the research fraud and
racketeering complaint data for the
USDOJ to prosecute; This video teaches you how to use the patent
databases to search for related conflict of interest or racketeering
data. In the patents you will find all sorts of language contradictory
to what the Lyme cabal or IDSA, now, uses publicly. Therefore, these
patents MUST all be studied and examined by you. These are legal patent
CLAIMS and therefore, for the most part, truthful. These individuals
can’t very well patent a non-truth or someone else will patent the
actual truth, useful for scientific history as well as commercially.
VID10 THE LYME CRYME PATENTS (Feb 15, 2015)
https://www.youtube.com/watch?v=XQB0VFZiKxg
See also:
Cryme Disease video playlist the rest of the playlist for more
crime facts.
This document is a companion (to the video) list of CDC officers and
ALDF.com/Yale/NYMC associates who own patents related to Lyme and other
TBDs; the Dearborn event was not only research fraud but
interest-conflicted, as were the FDA panels to approve LYMErix (they
were all the same characters: Steere, Barbour, Schoen, Rahn, Johnson,
Weinstein, McSweegan, etc). =====
A little
background about this Dearborn/OspA-scam, since it is the central or
essence of the crimes: “Dearborn” refers to the 1994 CDC conference
(took place in Dearborn, MI) where the testing for Lyme was falsified,
or changed from that which represented the Lyme spirochete as just
another relapsing fever organism,… to something else entirely contrived
(not even empirically perceived) and false. That event is discussed in
this video and the other ones in the YouTube series called “Lyme Crymes.”
For years, no one among this CDC/ALDF/Yale.NYMC cabal would admit that
rOspA (recombinant outer surface protein A of the Borrelia burgdorferi
organism or the Lyme vaccines that came and went) was Pam3Cys, because
they couldn’t. If they said “OspA is Pam3Cys,” everyone would know from
officialdom that it was never a vaccine and the ALDF.com’s (now IDSA’s)
whole house of cards would collapse. rOspA is a fungal antigen that
causes immunosuppression – the opposite of a “vaccine.” If OspA was not
a vaccine, then the CDC’s 1994 “Dearborn” 2-tiered testing schema was a
lie.
The falsified
Dearborn case definition was the lie invented to pass off bogus OspA
vaccines. You can tell for sure because they left OspA and B out (A and
B are encoded on the same plasmid so you can’t leave out one without the
other) of the diagnostic standard. One never tests for vaccine efficacy
with the same antigen that is the vaccine.
For example, if I made a recombinant measles vaccine based on a DNA
sequence that coded for say, “XYZ” surface antigen, I would not use
recombinant “XYZ” surface antigen in the testing schema to see if a
person had measles because I would not know if the antibody band was
from the organism or the vaccine.
It was known at least since the late 1980s that people with late
neurologic Lyme disease ceased to produce antibodies. However, the
Dearborn case definition (Steere, that is) rejected those classes of
disease – early and late meningitis or chronic neurologic cases - and
said instead that only the blatantly, highly immunoreactive class of
Lyme victims, those with the HLA-linked or arthritis-linked or
hypersensitivity-linked cases, or those who produced abundant IgG
antibodies could be called a “case” of “Lyme Disease.” This
falsification of the testing was as much a semantics game was it was
straight up research fraud from these DNA patenteers. This Dearborn
event left the sickest people with no disease diagnosis.
If I intended a
monopoly on a new diseases set or an entirely new class of diseases,
such as what African vector borne diseases arriving in North America
were discovered to be, what would I do? I’d make sure I got all of it:
vaccines, test kits, grants, funding, all future blood testing for all
future potentially patentable goodies in that blood, publicity, my name
on plaques and statues (like Alan Barbour), awards like an “Astute
Clinician Award,”… or, I could be knighted like Simon Wessely, a
psychiatrist who helps by calling all the victims of the Lyme scam and
Gulf War Illness “crazy” and “terrorists,” and US States naming, like,
“Allen Steere Day” after me…
The Dearborn stunt is to the present day, the lie these criminals are
trying to defend by issuing fake “guidelines” based on the fraudulent,
2001, Klempner non-retreatment report,
Two controlled
trials of antibiotic treatment in patients with persistent symptoms and
a history of Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/11450676
and with this cabal’s chronic hystrionics over the development of other
tests for Lyme, etc., because that, Dearborn, will be the most serious
criminal charge – the homicide charge. All the ALDF.com and DNA
patent-owners, here, have slandered and libeled against Lyme victims,
making this not a simply negligent homicide charge. All of their
derogatory slander and label and trash-talking Lyme and LYMErix victims
show “intent to cause harm,” which is not negligent homicide or
manslaughter, but murder and maiming.
Barbour, Alan G.,
CDC officer and
participant in the Dearborn conference, owns 30+ patents including the
ImmuLyme OspA patent. The ImmuLyme vaccine trial report authors (Sigal,
et al) and Barbour assert that one must be sure lipids are attached to
all Osps or else they will not be immunogenic, yet Steere’s Dearborn
panel was developed from high passage G39/40 and FRG with recombinant
OspA and B with no lipids attached, leaving OspA and B out of the case
definition panel.
Barbour’s ImmuLyme patent (&Berstrom, Magnarelli) European Patent #
(5092/88, DK)
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5523089.PN.&OS=PN/5523089&RS=PN/5523089
Yale’s LYMErix OspA patent (5,747,294):
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294
ImmuLyme trial result (falsified; used Dearborn, blots were unreadable):
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface
protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A
Lyme Disease Vaccine Study Consortium.
http://www.ncbi.nlm.nih.gov/pubmed/9673299
LYMErix trial result (falsified; used Dearborn, blots were unreadable):
Vaccination against Lyme disease with recombinant Borrelia
burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease
Vaccine Study Group.
http://www.ncbi.nlm.nih.gov/pubmed/9673298
Barbour says OspA
will not work as a vaccine due to antigenic variation, 1992:
Antibody-resistant mutants of
Borrelia burgdorferi: in vitro selection and characterization.
http://www.ncbi.nlm.nih.gov/pubmed/1339462
Fikrig and Flavell say OspA will not work as a vaccine due to “selection
pressure” or antigenic variation, 1995:
Selection of
variant Borrelia burgdorferi isolates from mice immunized with outer
surface protein A or B.
http://www.ncbi.nlm.nih.gov/pubmed/7729870
1992-1994. Steere
Falsifies Test in Europe: uses “high passage strains” and “OspA and B
without the lipid attached” to leave OspA and B out of the standard for
his later monopoly on vector borne diseases testing. Only Corixa,
Imugen and Yale were to be licensed to use the RICO strain patent by
Dave Persing (US Patent # 6,045,804)
Antibody
responses to the three genomic groups of Borrelia burgdorferi in
European Lyme borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/8106763
“The
group 1 strain of B. burgdorferi, G39/40, used in this study and in the
previous study of US patients was isolated from an Ixodes damini tick in
Guilford, Connecticut [21]. The group 2 strain, FRG [Federal Republic
of Germany], was isolated from Ixodes ricinus near Cologne [22]. The
group 3 strain, IP3, was isolated from Ixodes persulcatus near Leningrad
[23]. All three strains used in this study were high passage isolates,
which were classified by Richard Marconi (Rocky Mountain Laboratory,
Hamilton, MT) using 16S ribosomal RNA sequence determination as
described [11, 24]. The recombinant preparations of OspA and OspB used
in this study were purified maltose- binding protein-Osp fusion proteins
derived from group 1 strain B31 [25]. The fusion proteins contained the
full-length OspA or OspB sequence without the lipid moiety or the signal
sequence -" Full Text @
http://www.actionlyme.org/STEERE_IN_EUROPE.htm Dearborn:
http://www.actionlyme.org/DEARBORN_PDF.pdf See in the Dearborn booklet: none of the labs agreed with this Dearborn
proposal in that Dearborn pdf. (Except MarDx Labs, which was given
arthritis-positive blood to qualify their Western Blot strips prior to
Dearborn; MarDx was then was given both vaccine trial contracts; MarDx
was then sold to an company in Ireland, taking all the fraud data with
them; Trinity Biotech was the name of the company that bought MarDx). The CDC sent labs an invitation to participate, but then CDC blew them
all off:
http://www.actionlyme.org/DEARBORNINVITATION.pdf
Barbour also
patented Masters’ disease or STARI while the crooks played the DNA/RNA
shell game
http://www.actionlyme.org/PRIMERSHELLGAME.htm
to pull the wool over Edwin Masters’ eyes and to say “There is no ‘Lyme’
in Missouri or the south.” To patent a unique species, you have to
patent the flagellin gene. The same should be true for diagnostics –
using unique recombinant flagellins from all Borreliae.
Telford Phylogeny with Masters’ Amblyomma Borrelia:
Lone star
tick-infecting borreliae are most closely related to the agent of bovine borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/11158095
Barbour’s Patent
for Masters’ disease or something close to it [either lonestari or
barbouri; the phylogenetic data says they are the same in 16S RNA and
only slightly different in the flagellin gene (96% homology), so both
evolved from theileri, which is cow relapsing fever; one species is now
called barbouri and the other is called lonestari, but really they are
Masters disease, since he was the one who for years claimed there was a
Lyme-like illness in the south, associated with a Lyme-like rash and
tick bite]:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,932,220.PN.&OS=PN/5,932,220&RS=PN/5,932,220
Johnson, Barbara J., CDC officer, Ft.
Collins, CO., owner of 5 patents in Europe with SmithKline, talks about
differences in HLAs of mice, referring to their tendency to produce HLA-linked
hypersensitivity responses or not, meaning she is aware that the same
applies to humans. CDC’s BJ Johnson oversaw this Dearborn-Falsification-of-Lyme-Testing
stunt (Oct 1994). She said to not use high passage strains, yet high
passage G39/40 and FRG (Federal Republic of Germany) were what Steere
used to develop the Dearborn panel along with recombinant OspA and B
with no lipids attached. This was done, again, to assure OspA and B
were not included in the Dearborn panel, … to facilitate what Steere,
Corixa, L2 Diagnostics and Imugen intended to do after LYMErix was on
the market, … which was to monopolize the Lyme or tick-borne diseases
testing market where “the vaccination status was unknown.” RICO patent
6.045,804]
Johnson’s Patents
(5 in all):
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1
Dearborn Booklet
http://www.actionlyme.org/DEARBORN_PDF.pdf
Fikrig and Flavell
– own both the only scientifically valid
method to detect Lyme and also own the LYMErix OspA patent. ***Their
FDA-valid flagellin method was not used to assess the outcome of LYMErix
because they knew not only did LYMErix not work because Lyme is a
Relapsing Fever organism and undergoes antigenic variation (OspA itself,
Fikrig and Flavell said, undergoes antigenic variation or “selection
pressure” and would be no good as a vaccine), but Pam3Cys or TLR2/1
agonists (OspA is Pam3Cys) are fungal and cause immunosuppression in
most people – especially people without Steere’s alleged HLA-linked
hypersensitivity responses.***
OspA patent
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294
Fikrig and Flavell’s (Yale’s) Valid (per FDA) flagellin method patent
5,618,533:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,618,533.PN.&OS=PN/5,618,533&RS=PN/5,618,533
The PubMed report that goes with the Yale FDA-validated flagellin method
(detects 94.4% of all cases, including earliest and late neurologic),
1991:
Molecular
characterization of the humoral response to the 41-kilodalton flagellar
antigen of Borrelia burgdorferi, the Lyme disease agent.
http://www.ncbi.nlm.nih.gov/pubmed/1894359
Fikrig and Flavell
say OspA will not work due to antigenic variation:
Selection of
variant Borrelia burgdorferi isolates from mice immunized with outer
surface protein A or B.
http://www.ncbi.nlm.nih.gov/pubmed/7729870
Padula and OspC
– says Borrelia burgdorferi
strain B31 has little to no OspC in it, meaning whoever Western Blots
with this strain will be leaving OspA, B and C out of the standard. If
you have those bands, you will be told you do not have Lyme, yet they
are the “primary, immunodominant antigens,” which was why they got the
assignments A, B, C, etc. SmithKline used this strain, B31, to WB
LYMErix victims and claimed to be using the Dearborn method to detect
Lyme or vaccine failure.
Padula OspC patent: USPatent No.
5,620,862
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,620,862.PN.&OS=PN/5,620,862&RS=PN/5,620,862
Padula OspC – not in strain B31 PubMed report:
Molecular characterization and expression of p23 (OspC)
from a North American strain of Borrelia burgdorferi.
http://www.ncbi.nlm.nih.gov/pubmed/8225587
Persing, Schoen and the RICO-within-the-RICO patent
– this
patent shows the intention of Steere’s Dearborn, falsified case
definition (you will see later, in an announcement by the Mayo Clinic,
below).
US Patent #
6,045,804
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,045,804.PN.&OS=PN/6,045,804&RS=PN/6,045,804
This patent
reveals they know LYMErix causes a systemic disease like chronic Lyme,
and in this patent they reveal their intended monopoly on post-LYMErix
testing for the USA and Canada as they claimed in their advertising:
"Additional
uncertainty may arise if the vaccines are not completely protective;
vaccinated patients with multisystem
complaints characteristic of later presentations of Lyme disease may be
difficult to distinguish from patients with vaccine failure."
"The present invention provides a method useful to detect a B.
burgdorferi infection in a subject. The method provided by the invention
is particularly useful to discriminate B. burgdorferi infection from
OspA vaccination, although it is sufficiently sensitive and specific to
use in any general Lyme disease screening or diagnostic application. Thus,
the method of the invention is particularly appropriate for large scale
screening or diagnostic applications where only part of the subject
population has been vaccinated or where the vaccination status of the
population is unknown. "
Persing and Sigal
later reveal that the Western Blots in both vaccine trials were
unreadable. Both vaccine trials used MarDx test strips and said they
were using the Dearborn method to assess the efficacies of these
vaccines. Arthur Weinstein was the Data Safety Monitor for one of those
trials and was also a participant in the Dearborn scam. Obviously
Weinstein never looked at any of the data he was safety-monitoring since
the Western Blots were unreadable. In reality, neither OspA vaccine
trial group could tell whether or not OspA prevented Lyme, so those
vaccine trial reports were research fraud events and reports. This Persing-Schoen RICO-RICO Patent 6,045,804, is also written up this
PubMed report, co-written by Yale’s Robert Schoen:
Borrelia
burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA
vaccination from spirochete infection.
http://www.ncbi.nlm.nih.gov/pubmed/8968914
Dattwyler, Raymond J.
- owns a patent that describes OspA as Pam3Cys. Therefore it could
not have been a blood-stream-injected “vaccine,” because it is a human
TLR2/1 agonist. This Dattwyler patent is for an inhalation form of OspA/Pam3Cys.
Lung immunity is different from injecting fungal antigens directly into
the blood stream:
(US20090324638)
LIVE BACTERIAL VACCINE
"A lipidation/processing
reaction has been described for the intact OspA gene of B. burgdorferi.
The primary translation product of the full-length B. burgdorferi OspA
gene contains a hydrophobic N-terminal sequence, of 16 amino acids,
which is a substrate for the attachment of a diacyl glyceryl to the
sulflhydryl side chain of the adjacent cysteine (Cys) residue (at
position 17). Following this attachment, cleavage by signal peptidase II
and the attachment of a third fatty acid to the N-terminus occurs. The
completed lipid moiety, a tripalmitoyl-S-glycerylcysteine modification,
is termed Pam3Cys (or is sometimes referred to herein as Pam(3)Cys or
Pam3Cys). It has been suggested that the lipid modification allows
membrane localization of proteins, with polypeptide portions exposed as
immune targets. In addition to serving as targets for the immune
response, Pam3Cys-modified proteins, such as OspA, have been reported to
act as potent inflammatory stimulants though the toll-like 2 receptor
mechanism (TLR2).
http://patentscope.wipo.int/search/en/detail.jsf?docId=US42934470&recNum=9&maxRec=30&office&prevFilter&sortOption=Pub+Date+Desc&queryString=tripalmitoyl+cysteine+or+Pam3Cys+and+Epstein-Barr&tab=NationalBiblio
==========
The Mayo Clinic
advertised the RICO within the RICO – a patent they were the assignee
and would have gotten royalties (6,045,804); CT AG and now Senator
Richard Blumenthal’s staff were interested to know if this RICO cabal
including Yale, Imugen and Corixa ever advertised their intended
monopoly on post-LYMErix blood testing for North America “where the
vaccination status was unknown.” This is one example. Yale also
advertised this new test:
Can be found at:
https://groups.google.com/forum/#!original/sci.med.diseases.lyme/D6v-QHQdMbc/WupHjKwFilIJ
”http://www.mayo.edu/comm/mcr/news/news_361.html
“Mayo Clinic
Rochester News
“ Tuesday,
August 4, 1998
“New Tests Set
Standard for Diagnosing Lyme Disease
ROCHESTER, MINN. —
Mayo Medical Laboratories and IMUGEN Inc. announced today the newest and
most accurate test series available for diagnosing Lyme disease. The
tests also are the only reliable means of diagnosing Lyme disease in
people who have been vaccinated against Lyme disease.
“Mayo Medical
Laboratories, the laboratory for Mayo Clinic, and IMUGEN Inc. of
Norwood, Mass., are jointly offering the new proprietary tests through
local hospitals and clinics. Availability of the new tests coincides
with the anticipated release of new Lyme disease vaccines, such as the
widely-publicized LYMErix and ImuLyme. ”In research trials, all other Lyme tests have been shown to produce
false-positive results in people vaccinated against Lyme disease.
Moreover, the downstream costs of medical care delivered on the basis of
just one false-positive Lyme test can be as much as $15,000.
“According to Dr.
David Persing, a Mayo Clinic molecular biologist involved in the
discovery of the new test components, physicians now have a new and more
reliable means of diagnosing patients who present with symptoms of Lyme
disease.
"These tests
should help reduce the human and financial costs associated with the
number of undiagnosed, misdiagnosed, untreated or improperly treated
patients," Dr. Persing added. ”Scientists at IMUGEN, recognized nationally as the leading reference
laboratory for tick-borne diseases, are responsible for developing the
highly accurate immunologic methods to utilize Dr.Persing’s discovery.
"Diagnosing Lyme
disease has been highly problematic for a long time," said Victor
Berardi, chief executive officer of IMUGEN, whose laboratories have
performed more than a half-million Lyme disease tests. "Our new tests
will greatly help physicians in distinguishing patients who are actually
infected from those who aren’. Furthermore, the accuracy of these tests
will not be affected by Lyme vaccine. In any case, the tests will help
physicians render more appropriate and cost effective care."
“Lyme disease is a
tick-borne illness that if left undiagnosed or untreated can severely
damage the human heart and nervous system. Nationally more than 16,000
cases of Lyme disease were reported to the Centers for Disease Control
and Prevention (CDC) in 1996. The majority of cases were reported in New
England and the Northeast. The CDC reports that the overall number of
Lyme disease cases could climb to 25,710 by the year 2000.
“In a study of
10,936 people in states with a high incidence of Lyme disease, one new
vaccine proved 79 percent effective at preventing Lyme disease
infections after complete dosage. Given the potential popularity of the
vaccine, and the recent epidemic of Lyme disease in the Northeast, the
new tests offered by Mayo Medical Laboratories and IMUGEN will be of
considerable value. ”The new Lyme disease tests detect multiple classes of antibody isotypes,
enabling them to discriminate between the vaccine and a true Lyme
infection. Existing Lyme disease tests, however, have shown to produce
false-positive results in patients vaccinated for Lyme disease.
“IMUGEN Inc. of
Norwood, Mass., is a pioneer in the research, development and testing of
tick-borne diseases, including Lyme disease, babesiosis and ehrlichiosis.
For the past decade, IMUGEN has provided clinics and hospitals in the
Northeast with
high-quality
serologic testing from its facilities in Norwood, Mass., and
Southhampton Hospital in Southhampton, N.Y. For more information, call
781-255-0770.
“Mayo Medical
Laboratories is the laboratory for Mayo Clinic and provides lab services
to community-based healthcare organizations throughout the nation and
world. Mayo Medical
Laboratories draws
from the expertise of Mayo Clinic’s 1,600 physicians and scientists who
provide specialized consultation on test selection, utilization and
interpretation.
“For information,
call 800-533-1710. ###
“Contact:
“Tom Huyck
“507-284-0003
(days)
“507-284-2511
(evenings)”
-------------------------
CDC/ALDF’s
Valid Biomarkers in “Lyme Disease,” not used in Klempner/IDSA’s Lyme
disease “re-treatment” study, and “guidelines. ”
Here we
reveal the valid biomarkers of illness in “Lyme Disease” discovered by
the CDC’s ALDF.com (and later IDSociety.org) cabal, yet they were not
used for the assessments or outcomes of Mark Klempner’s Lyme disease
“re-treatment” study or IDSociety.org’s “Guidelines on the Diagnosis and
Treatment of Lyme disease.”
Through this contrast we demonstrate criminal acts of those responsible
for the Lyme disease scam. The scam was essentially the CDC
falsifying
the testing and “case definition” at a conference in Dearborn, MI (1994)
in order to falsely qualify their OspA and other patent outcomes. The
purpose of the Dearborn stunt was to falsely claim that “Lyme disease is
only an HLA-linked hypersensitivity or allergy response,” knowing
otherwise. Criminal charges will include “fraud with malice” because of
the slander and libel against their victims.
If “fraud on the
government” is performed by government employees “with malice” or intent
to cause harm, they do not have immunity from criminal charges. Those
chargeable in the criminal Lyme disease scam include CDC officers Allen
Steere, Alan Barbour, Barbara Johnson and Mark Klempner; NIH employee
Edward McSweegan; NYMC and Yale’s Durland Fish; and their associates
with the ALDF.com.
These perpetrators claimed that vector borne diseases were a "rich vein
of gold from which to mine…” patent royalties (Alan Barbour). There are
more quotes revealing clear malicious intent towards their victims in
the 2003 complaint to the UN about these crimes here, in a formal
complaint to the UN (which they answered by saying they needed volumes
of complaints):
http://www.actionlyme.org/UN_PETITION.htm
This science of fungal antigen-induced immunosuppression exposes 1) the
mechanisms that produce the Autism pandemic, 2) the nature of Bioweapons
(stealth, no antibodies), and that 3) the CDC and the NIH are
embarrassed that they allowed this bunch of clowns to run a
“OspA/Pam3Cys is a vaccine” scam. But spirochetes are not typical
bacteria. They are their own phylum and shed fungal antigens. They
might as well be called myco-chetes.
1. Mechanisms
that produce the autism pandemic parallel chronic Lyme disease
The link between Lyme disease (the real name is Relapsing Fever) and
Autism is the fungal antigen OspA (Pam3Cys). OspA and antigens like it
are shed all the time in borreliosis or Relapsing Fever (RF) in a
process called blebbing. This blebbing or shedding of fungal,
lipopeptide surface antigens has something to do with RF’s immune
evasion. But they cause immunosuppression, the reactivation of latent
herpesviruses, and also tolerance-spreading from TLR2/1-agonist
tolerance to viral (Harding, http://www.ncbi.nlm.nih.gov/pubmed/20660347)
and to other bacterial type tolerance, such as LPS/TLR4-agonists
(Redmond, http://www.ncbi.nlm.nih.gov/pubmed/16461741).
Thimerosal is put in
vaccines to prevent fungi. It has been known at least since the 1950s
that you can’t
inject fungi together with viruses into a mammal as
this causes the viruses to become activated and lethal (Mice infected
with mycoplasma plus a hepatitis virus: http://www.ncbi.nlm.nih.gov/pubmed/13109101).
Conversely,
pediatricians give children with cold viruses antibiotics to prevent
secondary ear infections because they knew one infection tends to invite
another. The CDC’s influenza mortality data does not directly mention
that the vast majority of deaths were due to the secondary pneumonia
infections. In the 1918 Spanish Flu pandemic, it was again the
secondary, mycobacterial infections that killed most people. In these
examples, you’ve see the very real dynamic of fungal-viral synergy
working in both directions: fungal infections assist viral, and viral
invections invite bacterial.
2. The nature of
bioweapons – stealth or no HLA- or hypersensitivity-response
The second reason the CDC does not want anyone to know about the
mechanisms of illness from spirochetes constantly shedding/blebbing
outer surface fungal lipoproteins and with antigenic variation
("multi-clonal populations overwhelm the immune system," Barbour’s US
Patent 6,719,983 and related), "even if infected with just one
spirochete" (http://www.ncbi.nlm.nih.gov/pubmed/14861181,
Barbour, et al, referenced that “single spirochete” report), is
that the description of a bioweapon happens to match Alan Barbour’s
"multiclonal populations... overwhelm the immune system." A bioweapon
will have no antibodies that identify the original detonator infection.
However,
others are leaking this information. And Russia knows the
NYMC-associated Russians were HLA-datapharming (meaning they were
looking at local populations’ HLAs) all over the world. Bioweapons are
not designed against a population who will make strong, robust, healthy
antibodies. Stealth bioweapons target populations where there is no
association to HLA groups that will produce many antibodies and
potentially identify the original infections. See “Ethnic Bioweapons” in
Wikipedia where the Russian Duma banned the export of their
populations’ DNA to America in 2007 for this reason.
3. NIH and CDC are
embarrassed that they allowed these scientifically incompetent people to
run "Lyme Disease.”
The fungal OspA
non-vaccines caused the same systemic, “multi-system” (Persing and
Schoen), “protean” (Luft) disease as “Chronic Lyme,” and the NIH and CDC
are terrified of everyone knowing how badly that has screwed up all U.S.
medical science for decades. The crooked USA “government” currently
stands behind the IDSA’s spin on short-term-treatment-only because they
know Late Neurologic Chronic Lyme is really about reactivated latent
herpesviruses and systemic fungal and bacterial diseases. It’s
AIDS-like.
If the USDA.gov and CDC wanted to hide an accidental release of the
modified-for-the-hard-bodied-Ixodes-tick African Bird Borreliosis anserina
(called burgdorferi now), they
certainly picked the wrong bumbling, obtuse, low-life gang to try to
pull it off. Deploying vicious, foul-mouthed, stalking, slandering,
libeling cowards who used criminal “anonymous internet harassment” and
all their other transparent and stupid lab stunts such as what Steere
did to falsify the Dearborn case definition and this moronic “Klempner
study,” was the wrong way to play it. Western society is just not
familiar with such vicious, aggressive sledgehammer “treatment” of very
sick people from a self-alleged “medical society.” Their aggressive
behavior towards very sick people is classic “defensive behavior” (means
aggressive behavior, believe it or not, but that’s psychiatry) and
betrays their guilt.
Post Sepsis Syndrome
Despite all this, the new news is that the NIH has endorsed the
description of all the similar chronic fatiguing illnesses – CFIDS, ME,
Fibromyalgia, Lyme and possibly Gulf War Illness - by Washington
University St Louis (wustl.edu) in summer of 2014, shown below. We’ll
just agree with them and call these diseases post-sepsis syndrome
(PSS). PSS implies ongoing, active infections, and not just the
post-septic shock’s well-known organ, tissue and immune system
damage. They, wustl and the NIH, refer to the herpesviruses, especially
Epstein-Barr in PSS.
Notice that that PSS description is in parallel
with what happens when a child is immunosuppressed naturally or is
immunosuppressed because she/he has a concurrent active bacterial
infection, and is vaccinated anyway. Or, in the cases where the vaccine
vial has been contaminated with mycoplasma [which is “myco” (which is
fungal)], which is like OspA, and causes immunosuppression and the lack
of antibody production. The child will get the viruses instead of the
protection, as reported by the CDC themselves. Congenital Rubella causes
Autism and that was the reason they decided to vaccinate against it in
the first place. Measles is also a neurotropic virus. We call the
general dynamic Fungal-Viral Synergy.
The “IDSA Guidelines” are intended to give the
appearance that the Lyme cabal believes the Dearborn case definition is
real. But most of the cabal members were present for the Dearborn
stunt. For example, Gary Wormser’s contribution was that the Steere’s
research-fraud criteria was only 15% accurate in IgG (detects 9/59
cases), or misses 85%.
In 1997 Mark
Klempner received a $4.7 million grant to perform research fraud and
then declare that more treatment does not help Lyme victims. The
IDSociety.org’s “Guidelines” on the diagnosis and treatment of Lyme
disease are based on this bogus Klempner report.
Two Controlled Trials of Antibiotic Treatment in Patients with
Persistent Symptoms and a History of Lyme Disease
http://content.nejm.org/cgi/reprint/345/2/85.pdf
There were
numerous fraudulent events in that Klempner study design and in the
results-reporting.
-
Klempner used
the falsified Dearborn case definition as the inclusion/exclusion
criteria. Dearborn was not FDA-valid, was invented via research
fraud by Allen Steere in Europe in 1992, and was not even a
consensus at that 1994 Dearborn consensus conference.
-
Two-thirds of
Klempner’s “re-treatment” victims never had IV ceftriaxone before,
yet he claimed he was retreating with the standard of care at the
time, which was 30 days of ceftriaxone. Two-thirds of those patents
were not "re-treated," so there is no data here to report.
-
Klempner also
did not report which DNA primers he used to detect “NO LYME” in the
spinal fluid of his victims (see the DNA & RNA Primers Shell Game).
It turns out Klempner used the OspA gene, which undergoes antigenic
variation and is not likely to be found with OspA primers from
spirochetes fresh out of a tick. And in fact, whenever Mark Klempner
did find such OspA-gene-positive-DNA in the spinal fluid of his
potential victims, he rejected them from the study. Not only did
Klempner say in his write up of the report protocol that if
they were positive for Bb DNA in the spinal fluid, they would be
rejected from the study—this actually happened. We know of at least
one person who had Bb DNA in her spinal fluid that Klempner rejected
from the study, yet Klempner did not report this. He said publicly
at the 2001 Rhode Island Diseases of Summer Conference at South
County Hospital that there were not any cases of DNA-positive Lyme
to be found among his study candidates. (We have him on audiotape.)
In
2005 Klempner wrote 2 important reports; one with a man named Kaplan at
UConn and another with Gary Wormser. In the report with Wormser, they
revealed that there were 2 kinds of Lyme: The Dearborn, HLA-linked
arthritis in a knee kind, and the other, the 85%, the neurological,
seronegative kind. Once again we heard Lyme arthritis cases—cases where
the patients are not actually sick—are the only ones allowed to have a
disease. That is, the only people who test positive to the false
Dearborn case definition have a genetic, HLA-linked arthritis or
hypersensitivity; the “C6 Peptide Test” is the same—it only detects Lyme
arthritis:
A case-control study to examine HLA haplotype associations in
patients with posttreatment chronic Lyme disease.
“Patients generally feel well aside from their arthritis
symptoms.”
http://www.ncbi.nlm.nih.gov/pubmed/16107953
In the report with Kaplan, Klempner reported that these people had no
neurological compromise and therefore their symptoms were psychiatric:
"Cognitive function in
post-treatment Lyme disease: do additional antibiotics help?"
"CONCLUSION:
"Patients with post-treatment chronic Lyme disease who have symptoms but
show no evidence of persisting Borrelia infection do not show objective
evidence of cognitive impairment. Additional antibiotic therapy was not
more beneficial than administering placebo." http://www.ncbi.nlm.nih.gov/pubmed/12821733
Everyone knows that's false. Mark Klempner himself reported extensively
about cognitive impairment and biomarkers of central nervous system
degradation. Klempner, in addition to finding that Lyme was not curable
with IV ceftriaxone—that is, it does not kill all the spirochetes, even
without cells to hide within—he found that the majority (79%) of Lyme
victims have a unique sign or biomarker of a nerve and brain degrading
enzyme called matrix-metalloproteinase-130.
Here are those 2 reports:
Matrix
metalloproteinases in the cerebrospinal fluid of patients with Lyme
neuroborreliosis.
"Neurologic
manifestations of Lyme disease include meningitis, encephalopathy, and
cranial and peripheral neuropathy….The 130-kDa MMP was found without the
92-kDa MMP9 in the CSF of 11 (79%) of 14 patients with neuroborreliosis
and only 7 (6%) of 118 control patients (P < .001). This pattern of CSF
gelatinase activity may be a useful marker for neuroborreliosis. http://www.ncbi.nlm.nih.gov/pubmed/9466528
FULL TEXT: http://www.actionlyme.org/Retro_Klempnerization.htm
and
Fibroblasts protect the
Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in
vitro.
"The Lyme
disease spirochete, Borrelia burgdorferi, can be recovered long after
initial infection, even from antibiotic-treated patients, indicating
that it resists eradication by host defense mechanisms and antibiotics….
The ability of the organism to survive in the presence of fibroblasts
was not related to its infectivity. Fibroblasts protected B. burgdorferi
for at least 14 days of exposure to ceftriaxone. Mouse keratinocytes,
HEp-2 cells, and Vero cells but not Caco-2 cells showed the same
protective effect. Thus, several eukaryotic cell types provide the Lyme
disease spirochete with a protective environment contributing to its
long-term survival."
http://www.ncbi.nlm.nih.gov/pubmed/1634816
FULL TEXT:
http://actionlyme.org/Mark_Klempner_Fibroblasts.htm
Mark Klempner also wrote in 1998 that OspA was the cause of anti-myelin
antibodies or probably contributed to the MS form of Lyme. (He may have
meant OspC, since that was my reading of Roland Martin's 1988 "Lyme
causes Multiple Sclerosis" report, but regardless, MS is not a
personality or anxiety disorder):
Is it thee or me?--autoimmunity in Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/10581067
http://actionlyme.org/KFORSCHNER_DISCOVERS_LYME_TOXIN.htm
According to Mark Klempner, Lyme is incurable, causes nerve and brain
degrading enzymes as a marker of this terrible disease, and antibodies
against OspA cause anti-myelin antibodies or causes MS. But later he
performed the research fraud reports where Lyme is nothing but
psychiatrically induced imaginings of disability and cognitive
dysfunction.
The other
biomarkers discovered by the same persons who libel us with the likes of
Munchausen’s and Munchausen’s-by-Proxy accusations?
A)
MMP-130 - Klempner as shown above.
B)
ROBERT SCHOEN and GFAp, or glial-fibrillary acidic protein. GFAp is
found in the CNS as a biomarker of glial cell degradation in late
chronic neurologic Lyme victims:
The Lyme Disease
Vaccine: Conception, Development, and Implementation
"Other
peripheral neuropathies and Lyme meningitis are also seen at this stage.
In late-stage disease, the central nervous system may be involved. A new
diagnostic test measuring glial fibrillary acidic protein in
cerebrospinal fluid may prove to be a useful tool for measuring such
involvement (20)."
http://annals.org/article.aspx?articleid=713400
C)
SIGAL and BARBOUR and Anti-heat-shock antibodies (anti-flagellar
antibodies)
H9724, a monoclonal
antibody to Borrelia burgdorferi's flagellin, binds to heat shock
protein 60 (HSP60) within live neuroblastoma cells: a potential role for
HSP60 in peptide hormone signaling and in an autoimmune pathogenesis of
the neuropathy of Lyme disease.
"Although Borrelia burgdorferi, the causative agent of Lyme disease, is
found at the site of many disease manifestations, local infection may
not explain all its features. B. burgdorferi's flagellin cross-reacts
with a component of human peripheral nerve axon, previously identified
as heat shock protein 60 (HSP60). The cross-reacting epitopes are bound
by a monoclonal antibody to B. burgdorferi's flagellin, H9724. Addition
of H9724 to neuroblastoma cell cultures blocks in vitro spontaneous and
peptide growth-factor-stimulated neuritogenesis. Withdrawal of H9724
allows return to normal growth and differentiation. Using electron
microscopy, immunoprecipitation and immunoblotting, and FACS analysis we
sought to identify the site of binding of H9724, with the starting
hypotheses that the binding was intracellular and not identical to the
binding site of II-13, a monoclonal anti-HSP60 antibody. The current
studies show that H9724 binds to an intracellular target in cultured
cells with negligible, if any, surface binding. We previously showed
that sera from patients with neurological manifestations of Lyme disease
bound to human axons in a pattern identical to H9724's binding; these
same sera also bind to an intracellular neuroblastoma cell target. II-13
binds to a different HSP60 epitope than H9724: II-13 does not modify
cellular function in vitro. As predicted, II-13 bound to mitochondria,
in a pattern of cellular binding very different from H9724, which bound
in a scattered cytoplasmic, nonorganelle-related pattern. H9724's effect
is the first evidence that HSP60 may play a role in
peptide-hormone-receptor function and demonstrates the modulatory
potential of a monoclonal antibody on living cells."
http://www.ncbi.nlm.nih.gov/pubmed/11860186
So
they're saying antibodies against flagellin causes some pathology, while
at the same time saying band 41 means nothing and you have a
non-disease. It happens to be for the very reason - says Barbour - that
antibodies against flagellin cause cross-reactive antibodies against
human heat shock protein-60 that there is no flagellin vaccine. So,
because the anti-flagellar antibody causes harm and damage, the crooks
say if you HAVE that antibody, it means you're psychiatric and don't
have a real disease.
D)
LENNY SIGAL and QEEG or electroencephalograms (Sigal = Munchausen's
accuser)
QEEG and evoked
potentials in central nervous system Lyme disease.
"Quantitative EEG, flash visual evoked potentials, auditory evoked
potentials to common and rare tones, and median nerve somatosensory
evoked potentials were obtained from 12 patients with active CNS Lyme
disease and from 11 patients previously treated for active CNS Lyme
disease. Abnormal QEEG and/or EPs were found in 75% of the active Lyme
disease patients and in 54% of the post CNS Lyme disease patients. Three
different types of neurophysiological abnormality were observed in these
patients includingQEEG slowing, possible signs of cortical
hyperexcitability, and focal patterns indicating disturbed
interhemispheric relationships. In patients tested before and after
treatment QEEG and EP normalization was associated with clinical
improvement."
http://www.ncbi.nlm.nih.gov/pubmed/7554300
http://www.actionlyme.org/MUNCHAUSENS.htm
in http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584
E)
ALLEN STEERE and Brain SPECT or Hypoperfusion
Reversible cerebral
hypoperfusion in Lyme encephalopathy.
"Lyme
encephalopathy (LE) presents with subtle neuropsychiatric symptoms
months to years after onset of infection with Borrelia burgdorferi.
Brain magnetic resonance images are usually normal. We asked whether
quantitative single photon emission computed tomography (SPECT) is a
useful method to diagnose LE, to measure the response to antibiotic
therapy, and to determine its neuroanatomic basis. In 13 patients with
objective evidence of LE, SPECT demonstrated reduced cerebral perfusion
(mean perfusion defect index [PDI] = 255), particularly in frontal
subcortical and cortical regions. Six months after treatment with 1
month of intravenous ceftriaxone, perfusion significantly improved in
all 13 patients (mean PDI = 188). In nine patients with neuropsychiatric
symptoms following Lyme disease, but without objective abnormalities
(e.g., possible LE), perfusion was similar to that of the treated LE
group (mean PDI = 198); six possible LE patients (67%) had already
received ceftriaxone prior to our evaluation. Perfusion was
significantly lower in patients with LE and possible LE than in 26
normal subjects (mean PDI = 136), but 4 normal subjects (15%) had low
perfusion in the LE range. We conclude that LE patients have
hypoperfusion of frontal subcortical and cortical structures that is
partially reversed after ceftriaxone therapy. However, SPECT cannot be
used alone to diagnose LE or determine the presence of active CNS
infection."
http://www.ncbi.nlm.nih.gov/pubmed/9409364
F)
STEERE and YALE on Lyme Causing Lupus: Antiphospholipid antibodies
(probably more likely to be due to the reactivated EBV, but we will look
more closely later)
Reactivity of
neuroborreliosis patients (Lyme disease) to cardiolipin and
gangliosides.
"A
subset of patients (50%) with neuroborreliosis (Lyme disease) showed IgG
reactivity to cardiolipin in solid phase ELISA. In addition, a subset of
patients with neuroborreliosis (29%) and syphilis (59%) had IgM
reactivity to gangliosides with a Gal(beta 1-3) GalNac terminal sequence
(GM1, GD1b, and asialo GM1). Anti-ganglioside IgM antibodies were
significantly more frequent in these two groups of patients compared to
patients with cutaneous and articular Lyme disease, primary
antiphospholipid syndrome, systemic lupus erythematosus and normal
controls. Correlative evidence and adsorption experiments indicated that
antibodies to cardiolipin had separate specificities from those directed
against the gangliosides. IgM antibodies to Gal(beta 1-3) GalNac
gangliosides appeared to have similar specificities since these were
positively correlated and inhibitable by cross adsorption assays. Given
the clinical associations of patients with neuroborreliosis and syphilis
with IgM reactivity to gangliosides sharing the Gal(beta 1-3) GalNac
terminus, we suggest that these antibodies could represent a response to
injury in neurological disease or a cross reactive event caused by
spirochetes."
http://www.ncbi.nlm.nih.gov/pubmed/8410057
FULL TEXT: http://www.actionlyme.org/STEERE_AND_LUPUS_LYME.htm
G)
JJ HALPERIN and Quin or quinolinic acid found in the central nervous
system, which is a product of the immune response against a bacterial
infection (JJ Halperin)
Neuroactive kynurenines
in Lyme borreliosis.
"In
patients with encephalopathy, serum QUIN was elevated with corresponding
increments in CSF QUIN. Lymphokine concentrations were not consistently
elevated. We conclude that CSF QUIN is significantly elevated in B
burgdorferi infection--dramatically in patients with CNS inflammation,
less in encephalopathy. The presence of this known agonist of NMDA
synaptic function--a receptor involved in learning, memory, and synaptic
plasticity--may contribute to the neurologic and cognitive deficits seen
in many Lyme disease patients...."
http://www.ncbi.nlm.nih.gov/pubmed/1531156
H)
HALPERIN, DATTWYLER, “Lyme Is associated with ALS”:
Immunologic reactivity
against Borrelia burgdorferi in patients with motor neuron disease.
"Of 19
unselected patients with the diagnosis of amyotrophic lateral sclerosis
(ALS) living in Suffolk County, New York (an area of high Lyme disease
prevalence), 9 had serologic evidence of exposure to Borrelia
burgdorferi; 4 of 38 matched controls were seropositive. Eight of 9
seropositive patients were male (8 of 12 male patients vs 2 of 24
controls). Rates of seropositivity were lower among patients with ALS
from nonendemic areas. All patients had typical ALS; none had typical
Lyme disease. Cerebrospinal fluid was examined in 24 ALS patients—3 (all
with severe bulbar involvement) appeared to have intrathecal synthesis
of anti-B burgdorferi antibody. Following therapy with antibiotics, 3
patients with predominantly lower motor neuron abnormalities appeared to
improve, 3 with severe bulbar dysfunction deteriorated rapidly, and all
others appeared unaffected. There appears to be a statistically
significant association between ALS and immunoreactivity to B
burgdorferi, at least among men living in hyperendemic areas."
http://www.ncbi.nlm.nih.gov/pubmed/2334308
FULL TEXT: http://www.actionlyme.org/ALSLYME47.htm
I)
STEERE and NITRIC OXIDE in the brain (by Allen Steere):
Borrelia burgdorferi
and Escherichia coli lipopolysaccharides induce nitric oxide and
interleukin-6 production in cultured rat brain cells.
http://www.ncbi.nlm.nih.gov/pubmed/7513330
J)
BENACH and Anti-ganglioside antibodies
Experimental immunization with Borrelia burgdorferi induces
development of antibodies to gangliosides.
"Patients with neuroborreliosis produce antibodies, mostly of the
immunoglobulin M (IgM) class, to gangliosides, particularly to those
with Gal(beta 1-3)GalNac terminal sequences. Lewis rats were immunized
with a nonpathogenic strain of Borrelia burgdorferi and with a
chloroform-methanol extract (nonprotein) of this organism (CM) to
determine whether antibodies to B. burgdorferi also recognized
gangliosides. Rats were also immunized with asialo-GM1 to determine
whether the elicited antibodies recognized antigens in B. burgdorferi.
Rats immunized with B. burgdorferi produced low levels of IgM antibodies
that cross-reacted with asialo-GM1 and GM1. Rats immunized with CM had
marked IgM reactivity to asialo-GM1 and GM1. Immunization with
asialo-GM1 resulted in antibodies that cross-reacted with B. burgdorferi
antigens. Although antibodies to B. burgdorferi were of both the IgM and
IgG classes, those to CM and to asialo-GM1 and GM1 were predominantly in
the IgM fraction. Reactivity of the IgM antibodies decreased after
adsorption with the heterologous and the homologous antigens, indicating
bidirectional cross-reactivity between CM, asialo-GM1, and GM1 and that
immunization with one produces antibodies to the other. There was no in
vivo deposition of Ig in peripheral nerves, nor was there nerve
pathology as a result of immunizations, but IgM antibodies to asialo-GM1
and CM recognized homologous antigens in the nodes of Ranvier of
peripheral nerves from nonimmunized rats. This immunization model
suggests that antibodies to gangliosides in Lyme disease have a
microbial origin and are potentially relevant in pathogenesis."
http://iai.asm.org/content/63/10/4130.full.pdf+html?view=long&pmid=7558329
K) 1989, PAUL DURAY in IDSA's journal with the most important biomarker
of all,.....
Clinical pathologic
correlations of Lyme disease.
"Immature B cells can also be seen in the spinal fluid. These cells can
appear quite atypical- not unlike those of transformed or neoplastic
lymphocytes." -- http://www.ncbi.nlm.nih.gov/pubmed/2814170
Full Text: http://www.actionlyme.org/IDSA_CLINIPATH_DURAY.htm
1992, Duray
again in 1992, in Steve Schutzer's review of the 1992 Cold Spring Harbor
Conference on Lyme:
Lyme Disease: Molecular and Immunologic Approaches
(book)
"On occasion, these atypical-appearing large lymphocytes have been
misinterpreted in biopsy by several laboratories as cells of a malignant
lymphoma or leukemia. Bb antigens, then, may stimulate growth of
immature lymphocytic subsets in some target organs, as well as in the
cerebrospinal fluid (Szyfelbein and Ross 1988). Usual bacterial
infections do not produce such lymphocytic infiltrates in tissue.
****These immunoblastoid cells in Bb infections at times resemble those
found in Epstein-Barr virus infections.**** Does Bb reactivate latent
virus infections in tissues? Do some tick inocula harbor simultaneous
infectious agents (ixodid ticks can harbor Rickettsiae, Babesia microti,
and Ehrlichia bacteria, in addition to Bb), producing multi-agent
infections in some hosts? Further studies can clarify these issues by
mans of tissue-based molecular probe analysis." -
Paul Duray, NCI, NIH, Ft. Detrick, at the 1992 Cold Spring Harbor
ALDF.com conference, published in Steve Schutzer's Lyme
Disease: Molecular and Immunologic Approaches (book)
2006, The NIH (NINDS’s MS-Lyme Group) group that discovered that ***
OspA *** was the cause of the MS/New Great Imitator outcome of Lyme
reporting in the New York Times in the summer of 2013 (Martin and
Marques, 2006); this article says these OspA like antigens constantly
shed by Borreliae cause immunosuppression in the humoral immune system,
but apparently a chronic inflammatory state in the central nervous
system:
Borrelia burgdorferi
Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes
but differentially regulates HLA-class II expression.
http://www.ncbi.nlm.nih.gov/pubmed/16783164
And this report means you might not even have anti-flagellar antibodies
(flagellin is a TLR5-agonist) after being exposed to shed fungal OspA
like antigens (TLR2/1-agonists):
Borrelia burgdorferi
lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5
in human monocytes.
http://www.ncbi.nlm.nih.gov/pubmed/16479520
2013, Same NIH MS-Lyme Group as above, Martin and Marques:
When Lyme Disease Lasts
and Lasts –
Jane Brody, NYTimes
"Complicating the picture is the fact that some people with PTLDS
symptoms apparently never had Lyme disease in the first place, Dr.
Marques said in an interview. There are other infectious organisms —
Epstein-Barr virus, for example — that can produce similar symptoms and
may be the real culprits."
http://well.blogs.nytimes.com/2013/07/08/when-lyme-disease-lasts-and-lasts/
2014, Wustl.edu discovers that sepsis is like Lyme, in that the
survivors of it are likely to have survived via the immunosuppression
(TLR2-agonist tolerance/Endotoxin tolerance), but the result is the
reactivation of latent viruses:
Dormant viruses
re-emerge in patients with lingering sepsis, signaling immune
suppression
"Patients with lingering sepsis had markedly higher levels of viruses
detectable in the blood, compared with the healthy controls and
critically ill patients without sepsis. Among the sepsis patients, for
example, the researchers found that 53 percent had Epstein-Barr virus,
24 percent had cytomegalovirus, 14 percent had herpes-simplex virus, and
10 percent had human herpes simplex virus-7.
"These viruses generally don’t lead to significant illness in people who
are healthy but can cause problems in patients who are
immune-suppressed. "
http://news.wustl.edu/news/Pages/27015.aspx
FULL JOURNAL REPORT, snippet…
Reactivation of
Multiple Viruses in Patients with Sepsis
“Sepsis
is the host's non-resolving inflammatory response to infection that
leads to organ dysfunction [1], [2]. A current controversial hypothesis
postulates that if sepsis pursues a protracted course, it progresses
from an initial primarily hyper-inflammatory phase to a predominantly
immunosuppressive state [3]–[7]. … However, several issues have limited
this approach including lack of consensus that immunosuppression is a
clinically important phenomenon [5], [6], [13]… Latent viruses such as
cytomegalovirus are normally held in abeyance by cellular and immune
surveillance mechanisms which if impaired, for example by
immunosuppressive medications, often result in viral reactivation,
replication, and virally-mediated tissue injury [15]–[20]. Sepsis
impairs innate and adaptive immunity by multiple mechanisms including
apoptosis-induced depletion of immune effector cells and induction of
T-cell exhaustion thereby possibly predisposing to viral reactivation
and dissemination [21]–[23]. …”
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0098819
2014, Here the NIH agrees that post-sepsis, like wustl above describes,
matches their own observations of what happens as a result of Chronic
Lyme (EBV reactivated; ie, that being generally accepted as the main
driver of MS and Lupus):
NEW, by the NIH:
Surviving Sepsis: Detection and Treatment Advances
By
Carolyn Beans for the National Institutes of Health | August 18, 2014
08:43am ET
http://www.livescience.com/47387-sepsis-diagnosis-treatment-research-nigms.html
Preventing Secondary Infections
"Some people who survive sepsis can develop secondary infections days or
even months later. A research team that included Richard Hotchkiss,
Jonathan Green and Gregory Storch of Washington University School of
Medicine in St. Louis suspected that this is because sepsis might cause
lasting damage to the immune system. To test this hypothesis, the
scientists compared viral activation in people with sepsis, other
critically ill people and healthy individuals. The researchers looked
for viruses like Epstein-Barr and herpes simplex that are often dormant
in healthy people but can reactivate in those with suppressed immune
systems. [Sepsis Has Long-Term Impact for Older Adults, Study Finds]"
In the end, one wonders how the CDC and IDSA get off saying Lyme has no
illness signs or is a somatoform disorder. As long as people don’t know
what OspA is, they’ll get away with this charade.
On USA’s Bioweapons from the Congressional Record, 103rd Congress:
"Methods of using antipersonnel agents undoubtedly vary so that no
uniform pattern of employment or operation is evident [make sure it does not produce antibodies, is the short
version- KMD]. It
is likely that agents will be used in combinations so that disease
symptoms will confuse diagnosis and interfere with proper treatment. It
is also probable that biological agents would be used in heavy
concentrations to insure [SIC] a high percentage of infection [or just use the OspA vaccine- KMD] in
the target area. The use of such concentrations [or
the multiple infections it causes, due to the immunosuppression like
HIV, Lyme, or LYMErix as acquried immune deficiencies - KMD] could
result in the breakdown of individual immunity because the large number
of micro-organisms entering the body could overwhelm the natural body
defenses [or
just infect or inject people with an immune suppressor like OspA from a
tick or a syringe, and the reverse will happen: people will acquire
multiple infections because their immunity is trashed by OspA- KMD].
It
is extremely important that people actually read that. It matches the
“single spirochete producing multiple variants” and “these multiple
variants each undergoing limitless antigenic variation…,” “could
overwhelm the immune system,” claims, especially if they are of the OspA
or fungal type.
Basically these crazy people associated with the CDC and ALDF.com wanted
to inject people with the very thing that causes the New Great Imitator
outcomes. It was like a Tuskegee “Bad Blood” experiment on steroids.
150219,KMD,SASH
LYMErix #FAILED
Anniversary Edition - Ordered off the market by the FDA.
Feb. 26, 2002, the FDA ordered
LYMErix off the market because it was causing systemic, "protean (please
look that word up)," "multi-system disease," just like Chronic Lyme (and ME/CFS,
which are identical). We had started a campaign to get these
events reported to the FDA per the recommendation - if you can believe it -
of Dennis Parenti at SmithKline in PA in Sep, 1999. About a month earlier
Karen Forschner of the Lyme Disease Foundation (Hartford, CT) had gotten me
a copy of the Dearborn booklet. (I actually ordered it on the phone from her
office in Hartford in June, 1999. I had gone up there to Hartford to
complain about the adverse events and said to Karen that we needed to know
how the hell we got this standard, since just about no one with Lyme tested
positive to Dearborn and also OspA and B were left out, yet they were the
"vaccine?" ....)
So, we knew LYMErix was causing "systemic, protean,
multisystem disease" just like Chronic Lyme from the patients - who we told
how to report to the FDA through the VAERS. It took another 4-5 years to
find out exactly what that molecule was, OspA (Pam3Cys). I found its image
in a Korean Chem journal as part of an HIV vaccine (?). Pam3Cys is FUNGAL,
explaining the "protean, multi-system disease," which starts out by causing
immunosuppression and a lack of apoptosis in infected cells. At the same
time, we knew EBV did the same thing - inhibited apoptosis of infected cells
- and such "EBV-transformed" or "EBV-immortablized" cells were found in the
spinal fluid of Lyme victims (Duray). And Dearborn
was bogus - I am an analytical chemist and development and validations of
analytical methods happened to be what I did for a living at Pfizer. Bogus
testing, bogus vaccine, .. and the disease was the same as the vaccine
outcome. Clue.
Everyone will recall that when I blew the whistle at
the FDA in Jan 2001, I showed the FDA committee that no one agreed with the
crooks at Dearborn at that 1994 meeting, and I also said that LYMErix caused
immunosuppression (IL-10 and Dattwyler's NK cell activity suppression).
I said this vaccine appears to be activating some latent infection...
It just took a while to figure
out why - I could find no structure for OspA for the longest time...
Article in the NJ Star-Ledger about LYMErix going down by Ed Silverman
"The decision was
a victory for consumer advocates, who have been lobbying the FDA to
force Glaxo to withdraw Lymerix.
“It should have
never been approved in the first place,” said Karen Forschner of the
Lyme Disease Foundation, a nonprofit that recently obtained
clinical-trial data that she said raised questions about the extent to
which side effects were recorded properly.
“It was based
on bad science. It’s a crummy vaccine that’s probably caused significant
injury to people, but information wasn’t shared with the FDA or the
public,” she said. “This decision will probably save thousands of people
from having similar problems.”
"Barbara Fisher,
who sits on the FDA advisory panel that last year heard testimony from
people claiming injury from Lymerix, agreed that Glaxo’s decision to
discontinue the vaccine was overdue."
SmithKline was actually issued an ultimatum by the FDA
to either withdraw it themselves or the FDA would order it off the market.
So, the truth was not that SmithKline voluntarily withdrew it.
SmithKline was threatened by the FDA to yank it themselves or the FDA
would yank it.
The same mechanism cross-applies in the cases of
children getting brain damage from vaccines. The CDC's and NIH's own
science reveals that the vaccination of children with fungal-contaminated
vaccines results in the vaccines being reactivated. In other cases
where the kids are getting the viruses instead of the "protection" are the
cases where the children are immune suppressed either naturally or because
they have some other ongoing infection. NEVER vaccinate a kid with a
cold, if you know what I am saying.
The same reasons doctors came up with the idea of
giving kids with colds antibiotics to prevent ear infections, is the same
dynamic we are talking about here. One infection sort of "invites" the
others, if you follow me.
More data here in
this comprehensive report that ties in all the CDC's. NIH's and BigPharma's
research on these matters of vaccination failures or exposures to molds as
mechanisms of Acquired Immune Deficiencies such as Autism, Chronic Fatigue
Syndrome, ME, Chronic Lyme, etc.
Same paper here:
New Science-Policy
paper on ME/CFS, using the IDSociety.org's own data and Policy-Papers.
So, what is the state of the science? See
Chapter 13 regarding IDSA's Policy
Papers on Detection of CNS Infections with Mass-Spec-PCR.
Such testing obviously won't go into any "test kits," sorry CDC & IDSA
DNA Profiteers Time to go to jail, fellas, over your DNA patenteering
for test kits and vaccine royalties. You effed up all science in
America for the last 30 years with your blind greed and you put this country
in all sorts of peril.
Update --- CDC on fungal
meningitis--
http://www.cdc.gov/meningitis/fungal.html
Notice that the CDC's diagnostic criteria ^^^ there matches exactly the
new Policy Paper by IDSA on using Mass-Spec-PCR to identify CSF
pathogens
HERE.
Fauci's patent for the treatment of Fungal
Meningitis (Chronic Fatigue, Chronic Lyme and LYMErix Disease):
"BACKGROUND OF THE INVENTION
"....Illustrative of specific disease states in treatment of which the
present invention can be applied are HIV infection and other diseases
characterized by a decrease of T-cell immunity, for example,
mycobacterial infections like tuberculosis and fungal infections such as
cryptococcal disease. This method also can be used in the treatment of
secondary infections that occur in patients with suppressed immune
systems, such as the opportunistic infections that occur in AIDS
patients. ..."
It's a patented treatment for the immune suppression outcomes of Lyme
disease, which is a condition simultaneously denied by the head of the
National Institute of Allergy and Infectious Diseases- who owns this
patent.
"It is an indescribable experience knowing that what you are doing
will have an impact on the lives… of millions of people." —Anthony Fauci,
1993
Yeah, thanks,
Ton'. It's been fabulous.
Ignore Vaccine Scare-mongering and Threats
No one should worry about the CDC or any of the MSM "news" outlets or
Zuckerheimer threatening to kick Anti-Vaxxers off Facebook or whatever
bullshit response we're getting because the incompetent HHS.gov lost control
of all narratives. They, the NIH, CDC, etc., totally lost control of
all narratives because they're dumb and have severe credibility issues (that
are really criminal issues and they are going to be charged in a few HUGE
ones this year).
And the American Medical Association totally endorses our position:
http://www.globalresearch.ca/american-medical-association-opposes-mandatory-vaccines-medical-ethics-statement/5430563
So, everyone be cool. We got this. All USA institutions
FAILED and we are not even interested in what they have to say about
anything.... even while we proceed with writing up the criminal charges for
the USDOJ. You will see it is all the same data. The larger
truths about medical science, the CDC, and BigPharma are the same truths
that will be exposed - and the CDC held accountable for - in the USDOJ
criminal charge sheets, two of which are on this homepage: Patents and
Biomarkers.
Just don't be distracted by their bullshit scare tactics. It's all
bullshit hysteria from a bunch of cowards. And there is no kinda low
life lower than a coward. The whole world instinctively finds cowards
despicable.
|